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Abstract 
 
Resistance development to parasiticides has been a problem in both terrestrial 
and aquatic environments. A major challenge exists in early detection of resistance 
emergence due to the low frequency at which resistant organisms can occur initially 
within a population and the difficulty in detecting these organisms. Emamectin benzoate 
is an avermectin compound which has been used effectively in the treatment of sea lice 
on farmed salmonids around the world. The main purpose of this thesis was to examine 
field collected sea lice abundance data and treatment records to estimate changes in the 
effectiveness of emamectin benzoate for treatment of sea lice (Lepeophtheirus salmonis) 
infestations on farmed Atlantic salmon (Salmo salar). 
The objectives of this thesis were: (1) to review and describe methods for the 
evaluation of sea lice treatment effectiveness, (2) to evaluate and establish if changes in 
effectiveness of emamectin benzoate for the treatment of sea lice (L. salmonis) on 
farmed Atlantic salmon in New Brunswick, Canada, had occurred from 2004 to 2008, 
and (3) to determine if there was evidence of differences in the temporal development of 
resistance to emamectin benzoate across L. salmonis life stages using data collected in 
both Canada and Scotland. 
Field collected data from New Brunswick salmon farms (2004 to 2008) were 
examined for temporal and spatial changes in treatment effectiveness in populations of 
L. salmonis. Data analysis was carried out in two parts: examination of trends in 
treatment effectiveness and L. salmonis abundance and an examination of multiple 
factors influencing post-treatment L. salmonis abundance and treatment outcome 
through the use of statistical models (linear and logistic regression). A reduction in 
treatment effectiveness was found from 2004 to 2008 and treatment effectiveness was 
found to vary by location.  
Further analysis was carried out to examine for possible differences in treatment 
effectiveness between different sea lice life stages. Life stages were categorized into two 
groups: adult females (gravid and non-gravid) and other mobile stages (pre-adult female, 
pre-adult male, and adult male). Sea lice abundance records following emamectin 
benzoate treatments from the west coast of Scotland (2002 to 2006) and from New 
Brunswick, Canada (2004 to 2008) were examined. Differences in treatment 
effectiveness were found between the two groups by year and location. Changes in sea 
lice sensitivity to emamectin benzoate were not synchronized in all life stages. A 
difference in the rates of resistance development between locations was noted, with 
resistance developing more rapidly in New Brunswick than in Scotland.  
In summary, this research examined methods for the evaluation of emamectin 
benzoate effectiveness for the control of sea lice. A reduction in emamectin benzoate 
effectiveness occurred over time and varied by location. In addition, resistance 
development was not synchronized in all sea lice life stages. These methods could help 
aid in the detection of resistance development in parasites. However, no single method 
is likely to suffice for monitoring changes in sea lice sensitivity. In future, coordinated 
analyses from both laboratory and field studies will likely yield the best results. 
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Chapter 1 General Introduction 
Sea lice are ectoparasitic marine copepods of the family Caligidae that are found 
worldwide on a variety of aquatic organisms. They feed on the mucus, skin and blood of 
fish resulting in varying levels of damage to the host. While low numbers of sea lice 
cause only minimal damage to the host, high numbers can result in severe effects and 
even death of the host fish. Although large numbers of sea lice have been associated 
with commercial fish farming around the world, as early as 1940 there were reports of 
sea lice causing severe damage and mortality in wild fish (White 1940). Under intensive 
salmon farming conditions, sea lice numbers can increase rapidly and cause serious 
problems as a result of the high density of available hosts (Murray & Peeler 2005, 
Robertsen 2011).   
1.1 Background  
Sea lice are the most common parasitic copepod known to infest fish in the 
marine environment. The species of interest to marine and brackish water cultured fish 
originate from the family Caligidae (Johnson et al. 2004). The two genera of interest to 
salmon aquaculture are Caligus and Lepeophtheirus (Pike & Wadsworth 1999) with 
over 250 known species of Caligus and over 150 species of Lepeophtheirus documented 
(Walter & Boxshall 2012). Lepeophtheirus spp. and Caligus spp. are found on 
Salmonidae of the genera Salmo (North Atlantic salmon and trout), Salvelinus (trout and 
charr), and Oncorhynchus (Pacific salmon) (Pike & Wadsworth 1999, Costello 2006). 
However, Caligus species are thought to be more generalist in host selection and can be 
found on a variety of fish (Pike & Wadsworth 1999).  
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Lepeophtheirus salmonis (Krøyer 1837) is considered to be a specialist, 
generally only being found on salmonids. However, in British Columbia, Canada, this 
parasite has been found on the threespine stickleback (Jones et al. 2006). Jones et al. 
(2006) confirmed that early stages of L. salmonis can exist on the threespine stickleback, 
which may act as a temporary host for L. salmonis.  
Of particular importance to salmon farming are L. salmonis and several Caligus 
species. Lepeophtheirus salmonis has been the most problematic species of sea lice on 
farmed Atlantic salmon (Salmo salar L.) in the northern hemisphere (Scotland, Norway, 
Ireland, the east and west coasts of Canada, and the United States), since severe 
infestations with this species can result in disease of the host fish leading to economic 
losses for fish farmers (Pike & Wadsworth 1999, Johnson et al. 2004). In Chile, the 
species known to be the most problematic is Caligus rogercresseyi (Boxshall & Bravo 
2000), while on the east coast of Canada and Scotland, Caligus elongatus (von 
Nordmann 1832) can be present in significant numbers. Caligus elongatus, while being 
commonly found on farmed salmon in these regions, is usually not of great concern to 
the health and welfare of fish. In British Columbia, L. salmonis is the species of most 
concern on farmed fish although outbreaks resulting in disease are uncommon, while the 
secondary species of interest is Caligus clemensi (Parker & Margolis 1964) (Johnson et 
al. 2004). The majority of current literature has involved L. salmonis and to a lesser 
extent Caligus species, with the majority of that literature pertinent to C. elongatus 
(Boxaspen 2006). 
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1.2 Sea lice biology 
This review will mainly pertain to L. salmonis and, to a much lesser extent, C. 
elongatus. Sea lice have a multiple stage life cycle with free-swimming or planktonic 
and parasitic phases. Adult female lice produce strings of eggs which hatch into first 
stage nauplii. There are two free-living planktonic naupliar stages and one free-
swimming copepodid stage. The copepodid is the infectious stage which locates and 
attaches to a fish thus beginning the parasitic phase. Once on the fish, there are four 
attached juvenile stages, known as chalimus, followed by the mobile stages consisting of 
two pre-adult and one adult. Each of the life stages is separated by a moult (Johnson & 
Albright 1991a, Johnson & Albright 1991b, Schram 1993). Copepodids moult into first 
stage chalimus and attach to the host by a frontal filament, while later pre-adult and 
adult stages move over the surface of the fish feeding on epidermal tissue (Heuch et al. 
2000, Boxaspen 2006). The sexes can be distinguished visually once the chalimus IV 
stage is reached and sexual maturation occurs in the later parts of the second pre-adult 
stage (Pike & Wadsworth 1999). Caligus elongatus has an eight-stage life cycle 
(Piasecki 1996), while L. salmonis consists of a ten-stage life cycle (Johnson & Albright 
1991a); C. elongatus lacks the pre-adult stage of the life cycle and matures from the last 
chalimus stage (IV) directly into an adult (Piasecki 1996).  
Nauplii and free-living copepodids are non-feeding and live off internal reserves 
derived from the remainder of the yolk sac. As this energy supply is limited, it is 
important that the copepodid find a host fish and attach prior to this source depleting. 
Nauplii have limited ability to swim (Bron et al. 1993), but potentially cover great 
distances by moving primarily with the current (McKibben & Hay 2004, Costello 2006). 
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The copepodid, however, is a more active swimmer than the naupliar stages which aids 
it in locating a host. Once the copepodid finds and attaches to a fish, it begins feeding as 
this stage has developed mouthparts and a functional gut (Pike & Wadsworth 1999). 
Heuch et al. (1995) found that copepodids may find hosts by moving through the water 
column and rising to the surface during the day and sinking down and spreading out 
through the deeper layers during the night. This positive phototaxis has also been 
witnessed in laboratory studies on sea lice (Hogans & Trudeau 1989, Pike et al. 1993). 
Caged salmon are known to rise to the surface to feed during the day but otherwise 
remain lower in the cage during day light hours, while rising closer to the surface during 
the night (Pike & Wadsworth 1999). Heuch et al. (1995) postulated that this movement 
through the water column facilitates several copepodid-fish interactions throughout a 24 
hour period. Copepodids are also influenced by salinity; their survival is reduced at 
salinities lower than 29% and they will actively avoid salinities below 27% (Bricknell et 
al. 2006).  
Adult female sea lice produce paired egg strings. The estimated number of eggs 
per string is variable.  Heuch et al. (2000) described finding approximately 55 to 704 
eggs per string while Schram (1993) reported observing 180 to 300 eggs per string. The 
length and number of eggs is dependent on age of the adult female sea louse, season and 
temperature. Adult females can produce multiple pairs of egg strings (Heuch et al. 2000, 
Mustafa et al. 2000). Heuch et al. (2000) found that adult females could produce as 
many as 11 pairs of egg strings with adult females surviving up to a maximum of 191 
days at 7.2 °C under laboratory conditions. In addition, the number of eggs produced 
varied with temperature, with more eggs produced at a lower temperature (7.1 °C) 
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versus a higher temperature (12.2 °C). However, a higher proportion of non-viable eggs 
was found at the lower temperature. Mustafa et al. (2000) found that up to ten pairs of 
egg strings per female (mean of six pairs) could be produced under laboratory 
conditions at 10 °C with adult females living for up to 210 days. Number and viability 
of eggs has been shown to increase with age of the adult female louse and each 
successive pair of egg strings. The first pair of egg strings produced by a female will 
have fewer eggs than subsequent rounds of egg strings (Schram 1993, Heuch et al. 
2000). 
Generation time of L. salmonis on Atlantic salmon held at 10 °C in the 
laboratory was determined to be 40 days for males (i.e. 400 degree days) and 52 days for 
females (Johnson & Albright 1991b). However, generation times have been found to 
vary considerably (Pike & Wadsworth 1999). Females mature more slowly than males 
and sea lice generation time can be affected by temperature, with a shorter generation 
time occurring with increasing temperatures (Johnson & Albright 1991b).  
A notable difference between L. salmonis and C. elongatus is size; L. salmonis 
adults are much larger than C. elongatus adults. Adult female and adult male L. 
salmonis differ in length with adult females being significantly longer than adult males, 
while there is minimal difference in length between the adult male and female C. 
elongatus (Johnson & Albright 1991a, Piasecki 1996). There is considerable variation in 
the size of adult L. salmonis depending on season, water temperature, location, and 
whether the lice are parasitizing farmed or wild fish (Tully & Whelan 1993). Tully & 
Whelan reported that sea lice on wild salmon were found to be considerable larger than 
those found on farmed salmon. Typically L. salmonis adult females tend to be larger 
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with decreasing water temperature or during winter months (Ritchie et al. 1993). The 
adult female L. salmonis is approximately 10 mm long whilst the male is approximately 
5 mm (Johnson & Albright 1991a). A detailed description of the life cycle and 
developmental stages of L. salmonis has been published by Johnson & Albright (1991a). 
1.3 Host-parasite relationship 
1.3.1 Impacts on host 
In the northern Atlantic Ocean, L. salmonis tend to cause the most damage to 
fish, most likely due to their size and more aggressive feeding (Pike & Wadsworth 
1999). While low numbers of sea lice on fish tend not to cause significant problems for 
the KRVWILVKKLJKQXPEHUVWKDWDUHEH\RQGWKHKRVW¶VDELOLW\WRFRPSHQVDWHFDQUHVXOWLQ
severe and, sometimes, life threatening issues (Pike & Wadsworth 1999). The quantity 
of sea lice required to cause serious damage to the host depends on size of the fish, 
species of fish, and species of copepod, but as few as five adult L. salmonis have been 
known to cause significant pathology on smolts (Wooten et al. 1982). Jones & 
Hargreaves (2009) estimated the threshold of lethal infection as 7.5 L. salmonis g-1 in 
juvenile pink salmon (Oncorhynchus gorbuscha). Fish infested with significant numbers 
of sea lice can display behaviours caused by irritation from the presence of sea lice. Fish 
may jump out of the water (i.e. flashing) more frequently or rub along the nets. Rubbing 
along nets may cause further external damage to the fish (Stone et al. 2002).  
Direct damage to the host fish is caused by the feeding activity of the sea louse. 
Chalimus stage sea lice cause slight damage around the area of attachment of the frontal 
filament, while the mobile, and more aggressive, pre-adult and adult stages can cause 
extensive tissue injury or destruction. Such aggressive feeding results in disruption of 
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the mucus layer followed by damage to the skin and subsequent loss of scales. With 
more severe damage, the lice will feed on blood and there may be exposure of 
underlying muscle or cartilage. The head is a particularly vulnerable area owing to the 
lack of scales and thinness of the skin. Fish with severe sea lice damage on the head 
penetratLQJWRWKHXQGHUO\LQJFDUWLODJHDUHFDOOHG³ZKLWHKHDGV´GXHWRH[SRVHGFDUWLODJH
(Pike & Wadsworth 1999).  
Indirect damage, such as osmoregulatory failure, can result from severe wounds 
to the skin and accompanying losVRIVFDOHVOHDGLQJWRWKHILVK¶VLQDELOLW\WRPDLQWDLQ
water and electrolyte balance within the environment (Pike & Wadsworth 1999). 
Consequently, host blood aberrations can occur, including a stress response leading to 
elevations in cortisol and glucose (Bowers et al. 2000), anemia, reduced lymphocytes, 
and ion imbalances (Dawson et al. 1999). Subsequently, such changes, along with 
physical disruptions of the skin, leave the host prone to secondary infections, such as 
vibriosis or furunculosis (Tully & Nolan 2002).  
Host infection can result in decreased feeding activity leading to reduced growth 
and specific growth rates. Dawson et al. (1999) found that pre-adult L. salmonis seemed 
to affect Atlantic salmon most severely resulting in significantly decreased food 
consumption compared to fish primarily infested with chalimus or adult sea lice. These 
fish were experimentally infected with sea lice, therefore, the sea lice were at similar 
stages in their life cycle at each of three sampling times (12, 21, 30 days post-infection). 
However, the total number of sea lice present decreased with time (i.e. there were fewer 
adult than pre-adult sea lice). Although food consumption decreased with the presence 
of pre-adults, specific growth rates of the fish were not affected. When the sea lice 
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moulted from pre-adults to adults, feed consumption increased and skin pathology 
improved. 
Susceptibility of salmonids to L. salmonis varies by fish species, with Atlantic 
salmon having a tendency to be more susceptible to infestation compared to some 
Pacific salmon species (Fast et al. 2002, Jones et al. 2006). Species differences have 
been associated with variations in skin, mucus, production of mucosal enzymes, and the 
ability of certain species to raise an inflammatory response to the sea lice (Wagner et al. 
2008). Atlantic salmon were found to have a thinner epidermal layer compared to 
rainbow trout or coho salmon (Fast et al. 2002). The study by Fast et al. concluded that 
coho salmon seem to have an innate ability to reject L. salmonis infestations, which may 
be related to the mucus biochemistry of the host. 
1.3.2 Impact on aquaculture 
There are a number of potential economic impacts as a result of sea lice 
populations that are difficult to control. Major costs are incurred with the purchase of 
parasiticides and equipment, human resources for monitoring and treatment 
administration, along with reductions in fish growth and feed conversion efficiency 
(Costello 2009). Sea lice were determined to be the most commercially limiting parasite 
in salmon aquaculture in Europe, along with North and South America (Costello 2009). 
Costello (2009) estimated the costs associated with sea lice infestations as equivalent to 
approximately 6% of the total production value.  
In 2009, the world production of Atlantic salmon was estimated at over 1.4 
million tonnes. The largest producer of Atlantic salmon in the world was Norway, which 
produced over 860 000 tonnes of salmon in 2009, followed by Chile with over 230 000 
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tonnes. Production in the United Kingdom was estimated at over 130 000 tonnes, 
whereas Canada produced approximately 100 000 tonnes of Atlantic salmon in 2009 
(Food and Agriculture Organization of the United Nations 2011).  
Not all countries where salmonids are produced are affected by sea lice. Costello 
(2009) speculates that limited production may impede the opportunity for sea lice 
epidemics to develop. Countries with lower production, such as Iceland, Russia, and 
France, tend not to have problems with sea lice infestations. Countries where Pacific 
salmon species are primarily cultured, such as coho salmon production in Japan and 
Chile, do not have significant problems with sea lice as coho salmon tends to be more 
resistant to infestations (Johnson et al. 2004). In addition, coho salmon production 
usually involves only one year in marine cages which may affect sea lice abundance 
since sea lice levels tend to be higher during the second year of production (Costello 
2009). 
1.4 Treatment and control measures for sea lice infestations 
There are several types of methods for control of sea lice: biological, 
management practices, and chemical. An example of biological control is the use of 
wrasse, a type of fish which are kept in ocean cages along with the farmed fish species. 
Wrasse will feed on sea lice infesting farmed fish (Treasurer 1993). Large numbers of 
wrasse have been regularly stocked on salmon farms in Norway (Treasurer 2002). 
Management practices, such as fallowing and year class separation, assist in keeping sea 
lice numbers low by reducing the exposure of young fish to lice sourced from older fish. 
Site location is an example of a management practice or environmental control where 
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farms are located in areas that are not conducive to a thriving sea lice population (i.e. 
areas with lower salinity or strong currents and flushing effects).  
1.4.1 Therapeutic options 
There are several therapeutic options available for treatment of sea lice. The 
options available to practitioners will vary by country since licensing regulations are 
different for every country. In Canada, most aquaculture therapeutants delivered through 
IHHGDUHUHJXODWHGE\+HDOWK&DQDGD¶V9HWHULQDU\'UXJ'LUHFWRUDWH9''XQGHUthe 
Canadian Food and Drugs Act and Regulations. When treatments are administered as a 
bath treatment to control external parasites in the aquatic environment, they are 
considered pesticides and are regulated under the Canadian Pest Control Products Act 
and Regulations. The Pest Management Regulatory Agency (PMRA) approves 
pesticides under the Pest Control Products Act. If a new drug is not marketed or 
registered for use in Canada, a veterinarian can submit a request through the Emergency 
Drug Release (EDR) program, administered by VDD, for use in a veterinary medical 
emergency. If a pesticide which is not approved by Health Canada is requested for 
emergency use by a practitioner or government body in Canada, an emergency release 
permit may be approved by PMRA under the Pest Control Products Act. Azamethiphos 
(Salmosan®), an organophosphate, and deltamethrin (AlphaMax®), a pyrethroid, are 
examples of products that have been approved temporarily in the recent past by PMRA 
for limited use in the Bay of Fundy, New Brunswick, Canada. Two drugs are currently 
approved by VDD for use in Canada: teflubenzuron (Calicide®), a chitin synthesis 
inhibitor, and emamectin benzoate (SLICE®) which is a type of avermectin.  
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1.4.2 Avermectins 
Avermectins are a class of macrocyclic lactones which were produced from a 
culture of Streptomyces avermilitis (Lasota & Dybas 1991). They have been used in 
human and veterinary medicine in addition to agricultural use for control of insects. 
Avermectins work by interfering with nerve transmission; they bind irreversibly to 
glutamate-gated chloride channels resulting in increased neuron cell membrane 
permeability to chloride ions at inhibitory synapses (i.e. hyperpolarisation) causing 
paralysis and death (Wolstenholme & Rogers 2005). As with other anthelmintic 
products used in terrestrial medicine, avermectins have been plagued with tolerance or 
resistance problems, which have been well documented in nematodes (Jackson & Coop 
2000, Le Jambre et al. 2000, Prichard 2001, Wolstenholme et al. 2004). 
1.4.2.1 Emamectin benzoate 
Emamectin beQ]RDWH´-deoxy-´HSLPHWK\ODPLQRDYHUPHFWLQ%1) is an 
avermectin product and is the active chemical in SLICE®. A 0.2% pre-mix was 
developed for use in aquaculture by Schering-Plough Animal Health (now Merck) under 
the trade name SLICE®. SLICE® is fully registered for use on salmon farms in Canada 
through the VDD. This product is administered in feed to the fish at a dose of 50 µg kg-1 
day-1 over the course of seven days and was found to be effective against all stages of 
sea lice found on host fish (Stone et al. 1999, Stone et al. 2000c). When fed to fish, 
emamectin benzoate is absorbed in the gut and distributed throughout the tissues of the 
fish. The focus of this research project was to evaluate changes in the effectiveness of 
emamectin benzoate because this product has been a popular choice for the treatment of 
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sea lice on farmed salmon and resistance development has become a concern in several 
areas (Horsberg 2012).  
Sevatdal et al. (2005a) determined the elimination half-life of emamectin 
benzoate in mucus on Atlantic salmon to be 11.3 days and that concentrations of 
emamectin benzoate were no longer detectable in plasma at day 77. Fish in the study by 
Sevatdal et al. were housed on a commercial salmon farm in Norway where water 
temperatures ranged from 15-19 °C. The highest concentration of emamectin benzoate 
occurred at the end of treatment administration (day 7) (Sevatdal et al. 2005a) or shortly 
after the cessation of medicated feed administration (Whyte et al. 2011). Sevatdal et al. 
(2005a) found concentrations of emamectin benzoate had a tendency to be higher in 
mucus than in blood or muscle. Kim-Kang et al. (2004) found emamectin benzoate 
levels to be below 85 ppb in skin and muscle samples of Atlantic salmon fed the product 
at the prescribed dose. Whyte et al. (2011) found concentrations of emamectin benzoate 
to be higher in skin than in muscle (approximately 4 times higher) when emamectin 
benzoate was given at the prescribed dose. Whyte et al. (2011) also found residue levels 
in skin to be higher than in previous studies (Kim-Kang et al. 2004, Sevatdal et al. 
2005a). Health Canada (VDD) has set administrative maximum residue limits (AMRL) 
for fish destined for human consumption of 1000 ppb in skin and 100 ppb in muscle 
(Health Canada 2012). Whyte et al. (2011) concluded that residue limits of this 
magnitude were not observed in muscle samples for the prescribed dose from day 5 
onward in the post-treatment period, while skin samples did not attain the AMRL at any 
point during the same period.  
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1.4.2.1.1 Review of studies evaluating emamectin benzoate 
Several studies evaluated emamectin benzoate efficacy in both the laboratory 
and field trial situations. Stone et al. (1999), evaluated emamectin benzoate as a 
treatment for sea lice on Atlantic salmon in a controlled laboratory trial. The objective 
of this initial study was to select a dose of emamectin benzoate which would be 
effective against all stages of the sea louse found on fish. The results of the study 
showed a significant decrease in mean mobile sea lice following treatment. The lowest 
optimum dose was found to be 50 µg kg-1 from the three doses evaluated (25, 50, 100 
µg kg-1).  
A field trial evaluation of emamectin benzoate efficacy was performed by Stone 
et al. (2000c). Efficacy of emamectin benzoate was evaluated against both L. salmonis 
and C. elongatus on Atlantic salmon housed in pens at a commercial salmon farm. The 
fish used for the study were post-smolts in their first year at sea with trials run in August 
and September. A third study on second year at sea fish was performed in April when 
temperatures were lower. Fish were dosed with emamectin benzoate mixed in feed at 50 
µg kg-1 biomass per day for seven consecutive days. Emamectin benzoate was effective 
in the removal of both mobile and chalimus stages of L. salmonis and C. elongatus with 
numbers reduced by 68-98% on treated fish. Sea lice damage was observed to be less 
severe on treated fish. This study found that treatment at lower temperatures resulted in 
slower removal of mobile stages of lice. As in a previous study (Stone et al. 1999), there 
was a gradual increase in chalimus numbers on treated fish, but little increase in mobile 
lice, suggesting that chalimus on treated fish had impaired development into mature 
mobile stages. Authors noted an improved feeding response in fish following treatment 
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and suggested that improvements in growth may be a benefit to in-feed treatments since 
bath treatments require several days of starvation and cause stress to fish during 
treatment administration. 
Stone et al. (2000b) evaluated the effectiveness of emamectin benzoate as a 0.2% 
aquaculture pre-mix (SLICE®) in a clinical situation on farmed fish in commercial pens. 
The trial examined the use of emamectin benzoate during autumn and winter months. A 
delay in efficacy was found in the winter trial compared to the autumn trial. Sea lice 
levels remained lower on treated fish than control fish with reductions of more than 90% 
up to day 64. The study concluded that temperature might influence the duration of 
efficacy.  
A subsequent study (Stone et al. 2000a) to examine the duration of effect of 
emamectin benzoate (using the 0.2% pre-mix SLICE®) in Atlantic salmon held in tanks 
in a laboratory confirmed that it was highly effective in reducing existing sea lice 
burdens (greater than 90%), but also prevented development of newly recruited sea lice 
for up to 62 days following start of treatment. 
Roy et al. (2000) examined the tolerance of Atlantic salmon and rainbow trout to 
emamectin benzoate. No adverse effects were found at doses up to 3.5 times the 
therapeutic dose and no mortalities occurred at seven times the therapeutic dose. Signs 
of emamectin benzoate toxicity in fish were lethargy, dark colouration, inappetance, and 
loss of coordination. At higher doses, emamectin benzoate is able to cross the blood 
brain barrier, resulting in neurological symptoms previously mentioned. A comparison 
of the toxicity of emamectin benzoate and ivermectin in fish was discussed by Sevatdal 
et al. (2005a) and Horsberg (2012); both papers concluded that symptoms and 
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mortalities occur more readily with ivermectin. The likely reason for these differences in 
toxicity symptoms is the ability of ivermectin to accumulate in the brain.  
Ramstad et al. (2002) evaluated emamectin benzoate (using the 0.2% premix 
SLICE®) in study pens at four commercial Atlantic salmon farms in Norway. In the 
study by Ramstad, they elected not to use control groups for fish welfare and 
commercial reasons. Instead, they chose to evaluate efficacy by determining a reduction 
in sea lice levels by comparing post-treatment counts with pre-treatment counts. 
Subsequently, this type of evaluation has been used in several other studies (Gustafson 
et al. 2006, Lees et al. 2008b). In Ramstad et al. (2002), the fish were in their first year 
at sea and all treatments occurred during summer months. Sea lice levels on fish treated 
with emamectin benzoate were reduced by over 90% at 21 days following treatment 
initiation.  
In Atlantic Canada, a field trial was performed to evaluate the efficacy of 
emamectin benzoate (using the 0.2% premix SLICE®) (Armstrong et al. 2000). The trial 
was performed at two commercial sea farming sites. Due to increasing numbers of sea 
lice on fish in the control groups, treatments with azamethiphos were required and baths 
with this agent were applied to each control pen at three different times. Treatment 
efficacy in this study was found to reach a maximum of 95% at days 28 or 29 of the 
study. The duration of efficacy was found to be approximately 43 days, after which sea 
lice began to slowly increase in number. Treated fish tended to have higher levels of 
copepodids.  
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1.4.2.2 Ivermectin 
,YHUPHFWLQKDVEHHQXVHGZRUOGZLGHLQWHUUHVWULDODQLPDOVVLQFHWKHHDUO\¶V
Ivermectin (22, 23-dihydroavermectin) is a semisynthetic avermectin registered for use 
in veterinary and human medicine (Lasota & Dybas 1991). Its mode of action is similar 
to that for emamectin benzoate. In some countries, ivermectin has also been used in 
aquaculture as an extra-label prescription (Horsberg 2012).  
Ivermectin has been used to treat sea lice on Atlantic salmon and is administered 
as an in-feed treatment. Ivermectin can be effective against mobile sea lice as well as 
chalimus stages (Johnson & Margolis 1993). Efficacy against chalimus stages is an 
important quality as this can extend the period of time between treatments (Roth et al. 
1993). Johnson & Margolis (1993) determined that a dose of 0.05 mg kg-1 fed twice per 
week would be efficacious in the treatment of sea lice (L. salmonis) on Atlantic salmon. 
There are some concerns with the use of ivermectin as a treatment for sea lice. 
Ivermectin has a narrow safety margin and can be toxic to salmon (Johnson et al. 1993b)  
which is in contrast to emamectin benzoate (Sevatdal et al. 2005a, Horsberg 2012). 
Johnson & Margolis (1993) found a significant increase in mortalities when increasing 
the dose from 0.1 mg kg-1 to 0.2 mg kg-1 (both administered every second day). Signs of 
toxicity in fish include a darkened colouration, loss of equilibrium, and decreased 
feeding activity. With a narrow margin of safety, one would have to be concerned with 
the possibility of inadvertent overdoses since there can be discrepancies between the 
prescribed dose and the actual dose attained by fish due to differences in feeding rates, 
poor drug distribution when mixing into feed, or inaccurate biomass estimation. 
Ivermectin likely remains present in fish tissues for extended periods of time since 
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efficacy has been found to be adequate at 28 days following treatment (0.05 mg kg-1 
every third day for six doses) (Johnson & Margolis 1993). Ivermectin is known to bind 
to sediments and breakdown is dependent on light and temperature. Its potential for 
accumulating in sediments beneath cages is a concern for susceptible benthic organisms 
(Roth et al. 1993, Horsberg 2012).   
1.4.3 Other treatment products 
1.4.3.1 Chitin synthesis inhibitors   
Teflubenzuron is a chitin synthesis inhibitor belonging to a group of compounds 
known as insect growth regulators. When a sea louse moults from one stage to another it 
produces a new chitinous exoskeleton. Chitin synthesis inhibitors disrupt the formation 
of a new exoskeleton (Horst & Walker 1995) during the moult between stages when 
demand for chitin is greatest. Teflubenzuron has been registered for use as Calicide® 
(Nutreco Aquaculture) and diflubenzuron has been manufactured and sold as Lepsidon® 
(Ewos). Calicide® or Ektobann® (Nutreco Aquaculture) are authorized for use in 
Scotland, Norway, Ireland, and the Faeroe Islands (Grant 2002) while Calicide® is 
available for use in Canada. Diflubenzuron has been used in Chile on a trial license 
(Grant 2002).   
Chitin synthesis inhibitors are administered in feed to salmon for the treatment of 
sea lice. These products are effective against only moulting stages of sea lice (i.e. 
chalimus and pre-adult stages). This product is not overly effective against adult stages 
because they have a decreased requirement for synthesizing chitin. Chitin synthesis 
inhibitors are most useful when few adult sea lice are present on the fish and the entire 
site is treated simultaneously (Branson et al. 2000). Although available for use in many 
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countries, teflubenzuron has not been a popular option likely due to its limited efficacy, 
particularly against adult stages as it is unable to break the reproductive cycle, and lack 
of extended residual effect (Campbell et al. 2006). 
1.4.3.2 Organophosphates 
Azamethiphos is an organophosphate used for the treatment of sea lice. 
Azamethiphos is marketed as Salmosan® by Novartis Animal Health Ltd., and licensed 
for use in Scotland, Norway, Faeroe Islands, Canada (until 2002) and Chile (Grant 2002, 
Burridge et al. 2010). When emamectin benzoate treatment failures in New Brunswick 
became evident in 2009, Salmosan® was one treatment option explored and PMRA 
issued an emergency permit for this treatment (Chang et al. 2011). Azamethiphos is 
administered as a bath treatment at a concentration of 0.1 mg L-1 (Burridge et al. 2010). 
As an organophosphate, the mechanism of action is through the irreversible inhibition of 
acetylcholinesterase (AChE) activity. Acetylcholinesterase decreases the activity of the 
neurotransmitter acetylcholine (at cholinergic synapses), thereby blocking the nerve 
impulse at the synapse. The inhibition of acetylcholinesterase by an acetylcholinesterase 
inhibitor results in overstimulation of the nerve impulses leading to spastic paralysis and 
death of the sea louse. 
Azamethiphos can be efficacious for the removal of pre-adults and adults but 
variable in the removal of chalimus stages (O'Halloran & Hogans 1996, Roth et al. 
1996). Some populations of sea lice in different areas of the world (e.g. Norway and 
Scotland in the early to mid-¶VGHYHORSHGUHVLVWDQFHWRRUJDQRSKRVSKDWHV(Jones et 
al. 1992, Denholm et al. 2002) and this resistance may remain within the population for 
years after product use has ceased (Fallang et al. 2004). The persistence of this 
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resistance in a population may lead to rapid onset of failed treatments if the product was 
to be re-introduced into the area.   
1.4.3.3 Pyrethroids 
Cypermethrin (Excis®) has been used in Scotland, Ireland and the United States, 
while high-cis-cypermethrin (Betamax®) and deltamethrin (AlphaMax®) have been used 
in Norway. Synthetic pyrethroids (i.e. synthetic analogs of pyrethrins) were developed 
as insecticides and act by altering (i.e. opening) the sodium channels thereby increasing 
nerve impulses resulting in spastic paralysis and death. These products are administered 
as bath treatments.  
With the development of a bioassay for deltamethrin, researchers were able to 
detect a decrease in sensitivity to deltamethrin in sea lice from an area with a history of 
treatment failures when compared with sea lice from other areas (Sevatdal & Horsberg 
2003). In a subsequent study, Sevatdal et al. (2005b) found that reduced sensitivity to 
pyrethroids was occurring occasionally; this study was conducted on sea lice collected 
from Ireland, Scotland, and Norway, some areas of which had anecdotal reports of 
treatment failures. 
1.4.3.4 Hydrogen peroxide 
Hydrogen peroxide is a strong oxidizing agent administered as a bath for the 
treatment of sea lice. Hydrogen peroxide had been used in Norway, Canada, Faeroe 
Islands and Scotland for the treatment of sea lice (Treasurer & Grant 1997) and has been 
relied upon more recently in New Brunswick, Canada, and Chile (Treasurer & Bravo 
2010). Hydrogen peroxide has been marketed under several names which include 
Salartect 350® or Salartect 500® (Brentage UK), as well as Paramove 35® or Paramove 
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50® (Solvay Interox). As it does not persist in the environment, hydrogen peroxide is 
rapidly converted to oxygen and water, this compound generates fewer concerns 
regarding potential ecological effects compared to other bath agents (Roth et al. 1993). 
The mechanism of action of hydrogen peroxide on sea lice is not well understood, but 
has been speculated to involve a mechanical paralysis resulting from the liberation of 
oxygen in the gut and hemolymph causing the lice to float up and off the fish 
(Thomassen 1993, Grant 2002).  
Hydrogen peroxide can be effective for the removal of adult and pre-adult 
stages, but the effect on chalimus stages can vary (Johnson et al. 1993a, Thomassen 
1993). Hydrogen peroxide can be toxic to fish and this is most notable with increasing 
water temperatures, exposure time (Johnson et al. 1993a, Thomassen 1993), and 
increasing dose (Grant 2002). Hydrogen peroxide treatments are not recommended at 
water temperatures above 14°C (Thomassen 1993). However, in Scotland, treatments 
with hydrogen peroxide have been safely performed in the summer at temperatures up to 
15°C by reducing the treatment time (Treasurer & Grant 1997).   
There has been a longstanding question about whether sea lice can recover 
following exposure to hydrogen peroxide and potentially re-infect fish (Hodneland et al. 
1993, Treasurer & Grant 1997, McAndrew et al. 1998). While Thomassen et al. (1993) 
did not report finding that lice would reattach after a bath treatment with hydrogen 
peroxide, Treasurer and Grant (1997) felt that this possibility might be underestimated. 
Even at treatment protocols high enough to cause mortalities of the host fish, high 
numbers of removed sea lice recovered following exposure (Johnson et al. 1993a). 
McAndrew et al. (1998) examined the ability of sea lice previously exposed to hydrogen 
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peroxide in a laboratory situation and determined that all mobile stages of L. salmonis 
were capable of re-infecting salmon after treatment with hydrogen peroxide. This 
finding is in contrast to Treasurer and Grant (1997) who found that, in a field situation, 
treated sea lice did not reattach to salmon, although the detached lice might have moved 
away from the farm with tidal currents.  
1.5 History of sea lice in Atlantic Canada 
Farming of Atlantic salmon in the southwestern Bay of Fundy region of New 
Brunswick, Canada, began in 1978. According to Statistics Canada, the annual harvest 
of Atlantic salmon has ranged from 24 000 - 26 000 metric tonnes for the years 2008 to 
2010 (Fisheries and Oceans Canada 2012). For the same years, production ranged from 
4 000 - 7 000 metric tonnes for Nova Scotia. 
During early production years, C. elongatus was the primary species found on 
salmon farms in the Bay of Fundy (Hogans & Trudeau 1989). In the fall of 1994, the 
first outbreak of L. salmonis involving multiple farms occurred (Hogans 1995, 
O'Halloran & Hogans 1996).  At that time, a variety of treatments were attempted with 
varying success, such as hydrogen peroxide, cypermethrin, ivermectin, and deltamethrin 
(Hogans 1995, O'Halloran & Hogans 1996, Chang et al. 2011). In the autumn of 1995, a 
time-limited registration was granted for the use of the organophosphate, azamethiphos 
(Salmosan®) as a bath (O'Halloran & Hogans 1996). Emamectin benzoate (SLICE®) 
ZDVLQWURGXFHGLQ1HZ%UXQVZLFNLQWKURXJK+HDOWK&DQDGD¶V(PHUJHQF\'UXJ
Release (EDR) program (Armstrong et al. 2000). For the next 9 to 10 years, this was the 
treatment of choice for several reasons: effectiveness against all life stages, prolonged 
efficacy post-treatment, and ease of administration in feed allowing for the simultaneous 
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treatment of multiple cages (Stone et al. 2000a, Stone et al. 2000c, Westcott et al. 2004). 
Reports of isolated treatment failures emerged in late 2008, initiating suspicions of 
emamectin benzoate resistance development. Starting in 2009, the industry and 
governing bodies had to consider other treatment options (Chang et al. 2011).  
1.6 Monitoring clinical use of emamectin benzoate 
Several studies have evaluated the clinical effectiveness of emamectin benzoate 
through examination of field-collected data in Scotland, United States (Maine), and 
Canada (British Columbia). Clinical trials are an ideal way to determine treatment 
efficacy, but often the use of medications in a true clinical situation can yield different 
results. The practice of monitoring clinical treatment response through the analysis of 
field-collected data remains a key factor in the detection of changes in treatment 
effectiveness. In this thesis, the term efficacy is used to refer to the measure of how a 
product works in a controlled trial or laboratory study, while effectiveness is used to 
refer to how well a treatment works in a clinical practice environment. Evaluations of 
treatment effectiveness usually involve a retrospective analysis. 
Gustafson et al. (2006) examined the effectiveness of emamectin benzoate on 
farmed Atlantic salmon in the Cobscook Bay region of Maine. Treatment episodes were 
selected based on the following criteria: counts included a minimum of five fish from 
each of five cages on a site and were performed at least every other week for eight 
weeks post-treatment. A total of 19 treatments across 11 different farms from 2002 to 
2005 were evaluated in the study. 
The use of a control group is common practice in most study designs. However, 
when assessing clinical use of a product, use of a control group is not always an option 
23 
 
due to concerns for animal welfare. Gustafson et al. (2006) described effectiveness as 
percent effectiveness which is the proportion of pre-treatment sea lice removed by the 
treatment [Effectiveness = 100 ± (average lice per fish post-treatment/average lice per 
fish at start of treatment)*100].  Most of the treatments in this study attained close to 
100% efficacy at some point in the post-treatment evaluation period. Lepeophtheirus 
salmonis numbers, as well as total Caligus sp. populations (a specific species was not 
specified, but C. elongatus would be the most common in that region) were evaluated. 
Maximum percent effectiveness and time to maximum effectiveness were calculated for 
each of the following life stages: chalimus, non-gravid mobiles (pre-adults and non-
gravid adults), and gravid females for L. salmonis. Caligus sp. was classified as total 
Caligus rather than individual life stages. Time to maximum effectiveness ranged from 
two to eight weeks following treatment initiation. Duration of treatment effect ranged 
from six to ten weeks. No determinations were made on the presence of a decline in 
treatment effect with time, although this might have been unlikely as all treatments 
appeared to be efficacious.  
Lees et al. (2008b) examined the effectiveness of emamectin benzoate against sea 
lice (L. salmonis) on farmed Atlantic salmon in Scotland. This study examined the 
clinical use of emamectin benzoate from 2002 to 2006. The following factors were 
examined in relation to treatment effectiveness and post-treatment sea lice abundance: 
location, time (i.e. year and season), age of fish (i.e. first or second year of the 
production cycle), and use of strategic treatment (i.e. single site treatment or 
synchronized entire loch treatment). Sea lice counts were evaluated as a group of total 
mobiles, which included pre-adult male and female, adult male, non-gravid and gravid 
24 
 
female sea lice. Treatment episodes meeting the following inclusion criteria were 
examined:   
1. Pre-treatment count within 16 days prior to the start of treatment;  
2. At least three post-treatment evaluations in the 12 weeks following treatment or 
until another treatment administration occurred (if occurring within the 12 
weeks); 
3. Entire site required treatment (i.e. no partial site or single cage treatments). No 
mixed treatment episodes were included (i.e. part of site was treated with one 
treatment and the rest with another); 
4. Site had to be treated with emamectin benzoate as medicated feed at a dose of 50 
µg kg-1 for seven consecutive days. 
This study by Lees et al. (2008b) was performed in two sections: first, treatment 
effectiveness and trends, and second, regression models to examine factors involved 
with treatment outcome and post-treatment lice counts. The first section examined post-
treatment mean abundance of sea lice and treatment effectiveness. Treatment 
effectiveness was determined to be a percentage of pre-treatment total mobile 
abundance = (mean post-treatment abundance/mean pre-treatment abundance * 100). A 
treatment episode was determined to be effective if values fell to less than 40% of the 
pre-treatment abundance at some point in the post-treatment evaluation. A general linear 
model was used to assess the importance of factors influencing post-treatment lice 
levels, such as region, year, season, presence of synchronized treatments, and stage in 
the salmon production cycle. 
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There were 185 emamectin benzoate treatment episodes available for review and 
108 treatment episodes met the inclusion criteria. In all years except 2006, the post-
treatment lice levels fell to below 45% of pre-treatment levels within 27 days of 
treatment. In 2006, the maximum effectiveness achieved was 35%. Time to maximum 
effectiveness was reached 29-34 days post-treatment with the lowest lice levels in the 
range of 21 to 62 days, similar to Gustafson et al. (2006). In this study, Lees et al. 
(2008b) found that post-treatment lice levels began to rise around the ninth week 
following treatment initiation. Duration of treatment effect has been reported as long as 
five months in the Broughton Archipelago region of British Columbia (Saksida et al. 
2007). In the linear regression model, post-treatment abundance was highest following 
winter (Nov-Jan) and spring (Feb-Apr) treatments, during the second year of the 
production cycle, and abundance varied by region. Increased sea lice abundance during 
the second year of the production cycle in Scotland has been noted in other studies 
(Revie et al. 2002b, Lees et al. 2008c). In summary, the authors determined that not all 
treatments evaluated were equally effective. This study showed that the effectiveness of 
emamectin benzoate varied between geographical region, time, and stage of fish 
production cycle.  
A follow-up short communication (Lees et al. 2008a), using the same data (Lees et 
al. 2008b), developed a logistic regression model to determine factors associated with 
ineffective treatment episodes. These data excluded the year 2002 as there were no 
ineffective treatments for that particular year. There were a total of 73 treatment 
episodes included in this model. Results indicated that ineffective treatment episodes 
were more likely to occur in the winter months and in the year 2006. Interestingly, pre-
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treatment lice abundance was included as a forced covariate and was found to be non-
significant, indicating that pre-treatment lice levels did not affect treatment outcome (i.e. 
success or failure). The mean pre-treatment abundance ranged from approximately 4 to 
15 mobile lice per fish. If pre-treatment sea lice abundance was found to be excessively 
high, then this finding may not hold true. At excessively high levels, fish may show 
signs of stress and decreased food consumption, thereby not ingest the emamectin 
benzoate in feed. Several other factors were included as predictor variables and were 
found to be non-significant: production year, region, and whether or not the treatment 
was part of a loch-wide intervention. Sensitivity analysis was run to assess the impact of 
changing the effective treatment criteria of 40%. Separate models were run where the 
40% cut-off was changed to 20% and 50% and only the statistically significant factors 
previously mentioned, year and season, remained. 
In 2010, Saksida et al., reviewed emamectin benzoate treatment data from British 
Columbia, Canada. SLICE® is the only product used for treatment of sea lice in British 
Columbia. Inclusion criteria were similar to that of previous studies conducted in 
Scotland (Lees et al. 2008a, 2008b). This study examined treatment episodes 
administered on farms in British Columbia between 2003 and 2008. Three years had 
treatment episodes meeting the inclusion criteria, 2003 (n=5), 2007 (n=11) and 2008 
(n=9). One of the study objectives was to determine if there was a decline in treatment 
effectiveness over time and, as it happened, the episodes included the first year and the 
last two years of the study. The majority of treatments were administered in the autumn 
or winter months and during the second year of production. A number of farms did not 
need to treat for sea lice during this time; the proportion varied from 18% in 2004 to 
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58% in 2007. The frequency of annual treatments remained fairly constant in British 
Columbia between 2003 and 2008. No significant differences were found between pre-
treatment lice counts across years. Treatments for all years were found to be effective, 
resulting in the reduction of sea lice counts to 3 mobile L. salmonis or less for at least 
three months following treatment. For all years, sea lice levels had fallen to below 20% 
of pre-treatment levels by one month post-treatment and, for the remaining follow-up 
period, the majority of sea lice levels remained at 10% or below the pre-treatment levels. 
The authors concluded that there was no evidence of a decline in treatment effectiveness 
on salmon farms in British Columbia from 2003 to 2008.  
1.7 Resistance development in parasiticides 
Two terms requiring clarification are the difference between tolerance and 
resistance development. Drug tolerance refers more to unconfirmed instances of an 
organism surviving a treatment with a product. This trait is not necessarily heritable and 
may be a transient property. Drug resistance refers to genetically based development of 
an orgDQLVP¶VDELOLW\WRVXUYLYHIROORZLQJWUHDWPHQW7KHVHWUDLWVDUHKHULWDEOHWRWKH
next generation. The above terminology was adapted from principles used in weed 
science pertaining to herbicide resistance (Technology Notes 1998). 
Resistance development to macrocyclic lactones used in the treatment of 
parasites in terrestrial animals has been well documented and appears to be a 
consequence of repeated use in populations (Prichard & Roulet 2007, Wolstenholme & 
Kaplan 2012). A variety of mechanisms can result in resistance development of an 
organism to a treatment product. The mechanism of resistance will usually involve 
decreased absorption or uptake of a product, or changes in how the product is 
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metabolised by the organism (Wolstenholme et al. 2004). It is likely that the genes 
conferring resistance already exist in the population and resistance emergence is 
inevitable when treatments inadvertently select for these resistance factors. In essence, 
those parasites with genes conferring resistance have a selective advantage for survival 
over more sensitive parasites. The rate at which resistance develops can depend on a 
multitude of factors such as: potency of resistance mechanisms, frequency of 
chemical/pesticide use, and biology of the parasite (Denholm et al. 2002).   
The development of treatment resistance in sea lice has become problematic for 
intensive salmon farming regions around the world. Resistance, or at least tolerance, has 
been noted in sea lice toward organophosphates, dichlorvos and azamethiphos, in 
Scotland and Norway (Jones et al. 1992, Roth et al. 1996, Devine et al. 2000). 
Resistance in sea lice to azamethiphos has been documented at a molecular level in adult 
female sea lice from Norway, but was less evident in Canada (Fallang et al. 2004). 
Reduced sensitivity through use of bioassays to deltamethrin has been documented in a 
population of sea lice in Norway with a history of treatment failures (Sevatdal & 
Horsberg 2003). A reduction in sea lice (C. rogercresseyi) sensitivity to emamectin 
benzoate in Chile was documented using bioassays (Bravo et al. 2008).  
Previous studies have also noted some life stage differences in resistance 
development. Roth et al. (1996) found differences in the sensitivity patterns of different 
life stages with the use of azamethiphos. They found that adult females were less 
sensitive while pre-adult males appeared to be the most sensitive. Treasurer et al. (2000) 
also found that gravid females were less sensitive to hydrogen peroxide than other 
mobile stages of sea lice.   
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Often the mechanism of resistance development is unknown and this can delay 
detection of resistance. Bioassays can aid in the detection of changes in sensitivity 
patterns when the resistance mechanism is unknown (Denholm et al. 2002). While a 
useful diagnostic tool, they are often labour intensive and require multiple replicates to 
ensure that results are accurate (Westcott et al. 2008). Bioassays are used to measure the 
concentration of a product required to achieve a predetermined effect on an organism 
and have been used as a method of resistance detection. The sensitivity of that organism 
to the product of interest is determined using an EC50 value which is the concentration 
that immobilizes 50% of the target organisms. For a detailed explanation of the methods 
used for laboratory bioassays with sea lice, see Westcott et al. (2008). With the 
confirmation of changes in sensitivity patterns, further testing is required. Use of 
molecular tests, such as PCR (polymerase chain reaction), which could detect gene level 
resistance, would be ideal. However, tests at the molecular level require detailed 
information on the mechanism of resistance.  
1.7.1 Resistance development in avermectins (emamectin benzoate) 
Resistance to macrocyclic lactones have been observed (Prichard & Roulet 
2007). Le Jambre et al. (2000) found that resistance to ivermectin in Haemonchus 
contortus, a pathogenic nematode of ruminants, showed strong indications of resistance 
development being sex-linked or sex-influenced, but only at the adult stage. They noted 
that in adult stages, males appeared to be more susceptible to the drug than females. 
Although an interesting finding for resistance development research, results found in 
nematodes may be difficult to extrapolate to arthropods, including sea lice.  
30 
 
P-glycoproteins have been associated with resistance development in nematodes, 
including H. contortus, and may be an accurate marker for resistance emergence 
(Prichard 2001). P-glycoprotein is an ATP-binding cassette (ABC) transporter protein 
which moves a variety of substances across cell membranes. Avermectins are good 
substrates for P-glycoprotein which act by removing avermectin from the cell through 
WKHWUDQVSRUWHUSURWHLQ7KLVUHPRYDOGHFUHDVHVWKHGUXJ¶VDFFHVV to the target sites and, 
thus, decreases concentration at the receptors. Macrocyclic lactones each have different 
affinity as a substrate for P-glycoprotein (Lespine et al. 2007). It has been suggested that 
emamectin benzoate may be a better substrate for P-glycoproteins and more readily 
transported than ivermectin (Igboeli et al. 2012). An increase in P-glycoprotein is 
thought to result in more rapid removal of the drug from nematodes (Wolstenholme et 
al. 2004). Prichard and Roulet (2007) reviewed resistance development in macrocyclic 
lactones and suggested that increased expression of ABC transporters may be the 
primary mechanism responsible for resistance emergence. Overexpression of mRNA for 
P-glycoprotein has been associated with emamectin benzoate exposure and has been 
linked to possible resistance development in sea lice to emamectin benzoate (Igboeli et 
al. 2012).  
1.8 Evaluations of sea lice populations on farmed salmon 
Revie et al. (2002b) reviewed historical sea lice (L. salmonis) counts in Scotland 
from 1996 to 2000. Abundance data were analysed in association with several key 
factors: year, stock type, region, coastal exposure, and level of treatment. Mean 
abundance of L. salmonis varied by year and was found to be significantly higher on fish 
during the second year of the production cycle. No significant differences were found in 
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sea lice numbers on farmed salmon between geographical regions or between farm 
locations (e.g. closer to the shore versus those with more coastal exposure). Temperature 
was not found to be a significant factor in sea lice abundance, which differs from what 
was found by Boxaspen (1997). Intensity of treatment did appear to have a major impact 
on the level of sea lice found on fish; the authors found evidence of a six week treatment 
intervention cycle.   
Subsequent to the above study, Revie et al. (2003) expanded on epidemiological 
factors affecting L. salmonis populations on farmed Atlantic salmon in Scotland using 
general linear models. Factors influencing mobile sea lice abundance, both within 
management control and those outside farm management control were examined. Sea 
lice populations were split into six month periods resulting in three divisions of 
populations: the last half of the first year in ocean net pens, the first half of the second 
year, and the second half of the second year. This allowed for evaluation of factors at 
different times during the production cycle. The first six month period of the first year in 
net pens was not examined as sea lice levels are generally quite low during this period of 
time. Significant factors in the model within management control were: treatment level, 
treatment type, and cage volume; while non-significant factors included stocking 
density, biomass, strategic treatment, neighbours with poor management practices, and 
length of fallow period. Factors outside of farm management control found to be 
significant were current speed and flushing; while non-significant factors were water 
temperature and current pattern. It is important to note that there were likely other 
variables, such as salinity, which may have influenced mobile sea lice abundance, but 
these could not be investigated due to inadequate availability of data. The inclusion of 
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sea lice abundance from the preceding six months was found to increase the variation 
explained by the model. The most unexplained variation occurred during the last six 
months of production where the only factor of significance was treatment type.  
Furthermore, Revie et al. (2003) found that temperature was not a significant 
factor affecting sea lice abundance, while other studies have found the opposite to be 
true (Johnson & Albright 1991b, Boxaspen 1997, Tucker et al. 2000). The temperature 
range in that study was 6.0-13.2 °C. Many of these studies were laboratory-based 
experiments and this may emphasize that differences can be found between laboratory 
and field results. Boxaspen (1997) found that sea lice abundance variations were 
correlated with temperature resulting in increased abundance at higher temperatures (> 
6°C). This was a study where small cages containing salmon were placed at four sites 
(i.e. one in the middle of a salmon farm, one at a fallowed salmon farm site, and two at a 
salmon farm with one closer to inshore and the other offshore from the farm). The study 
covered most months of the year and temperatures in Norway can range from 2.5-19.5 
°C. There was a significant increase in lice abundance from 1993-1994 to 1994-1995 
(i.e. greater than double) and this corresponded with a change in temperature. However, 
the difference in temperature was small; 1993-1994 was found to be 0.68 °C lower than 
long-term average, while in 1994-1995 it was 0.38 °C higher than the average. This 
study concluded that the differences in abundance levels may have been due to changes 
in temperature. With such a small difference in temperature, the possibility of other 
unmeasured variables influencing sea lice abundance, such as other fish as reservoirs for 
infection and water current/flushing speed, could not be ruled out. 
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In addition, Revie et al. (2003) found no association between length of fallow 
period and sea lice abundance. The fallow period was dichotomized into short or long 
periods, with long periods being in the 70-80 day range while the short periods were 
approximately 40 days. This finding is in contrast to a previous study which evaluated 
length of fallow period. Bron et al. (1993) concluded that the use of longer fallow 
periods was more effective than short fallow periods. However, this evaluation used a 
small data set from two Scottish sites, one with a long fallow period and one with a short 
period. While neither study determined the appropriate length of a fallow period, the use 
of such practices remains an important factor in control of sea lice levels especially 
during the early months after smolt transfer. 
In 2003, Heuch et al. compared epidemiological patterns of sea lice infestation 
between Scotland and Norway. Some of the more interesting differences were related to 
farming practices. In Norway, cages were larger and deeper than in Scotland where pen 
depth did not change throughout production. Scotland tended to have single year class 
sites, while Norway had a mix of farms, with only 38% of sites holding fish of a single 
generation. In Scotland, farms tended to be stocked with fish over a period of less than 
three months (spring), while Norway stocked fish at various times between April and 
November. Norway was less likely to practice fallowing, while Scotland typically 
fallowed their sites between two and four months. Scotland tended towards higher lice 
abundance, higher infection pressure, and more treatment applications. Cleaner fish 
were used by 47% of Norwegian farms. Norway (2.5-6.4°C) has lower winter 
temperatures than Scotland (5.5-9.2°C), as well as an overall wider range of 
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temperatures throughout the production cycle. Both locations were coldest in March and 
warmest in August.  
Saksida et al. (2007) evaluated sea lice (L. salmonis and C. clemensi) abundance 
levels on farmed Atlantic salmon in the Broughton Archipelago from 2003 to 2005. 
They found the lowest levels occurred between June and September and increased 
through the autumn and winter months. For the full sampling period, higher numbers of 
mobile sea lice of L. salmonis and C. clemensi were found on second year fish compared 
to first year fish. There were no significant differences found in the inter-annual 
variations of mobile L. salmonis populations which were separated into year 1 and 2 
classes.  
In British Columbia, there was a mean of 1.6 treatments per production cycle 
and these treatments consisted of only emamectin benzoate (Saksida et al. 2007). The 
majority of treatments in British Columbia were applied during winter and spring 
(October to March), while in Scotland and Norway treatments tended to occur most 
frequently during summer and fall months. In British Columbia, the average farmed 
salmon population resided in seawater for almost nine months before requiring their first 
treatment. The number of treatments per production cycle was significantly less in 
British Columbia compared to those reported in Scotland and Norway. Revie et al. 
(2002a) found an average of 2.1 and 6.5 treatments per farm per year in year 1 and year 
2 respectively in Scotland (1996-2000), while Heuch et al. (2003) found approximately 
two treatments per farm per year in year 2 populations in Norway (i.e. less than one 
third of treatments used in Scotland) (1997-1999). For the other studies performed in 
Scotland and Norway, there were a variety of treatments, none of which were 
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emamectin benzoate, as this was prior to the use of emamectin benzoate. Since bath 
treatments have little, if any residual effect, shorter periods of low level sea lice 
infestations would be expected to result in a higher frequency of treatment application, 
HVSHFLDOO\ZLWKKLJKH[WHUQDOLQIHFWLRQSUHVVXUH7KHOHQJWKRIWKH³OLFH-IUHH´SHULRGLQ
British Columbia and the generation time for lice reproduction at ambient water 
temperatures suggests that re-infestation from within a farm following an effective site-
wide treatment is unlikely. Clinical effects from sea lice infestations are rarely reported 
on farmed fish in British Columbia unlike other salmon farming areas (Hogans 1995, 
Armstrong et al. 2000, Johnson et al. 2004).  
Lepeophtheirus salmonis abundance was generally lower in British Columbia 
(Saksida et al. 2007) than in similar reports from farm-based data in Scotland and 
Norway (Revie et al. 2002a, Revie et al. 2002b, Heuch et al. 2003). Regardless of 
production area, sea lice levels increase the longer the fish are exposed to seawater 
(Revie et al. 2002a, Revie et al. 2002b, Tully & Nolan 2002). The proportion of adult 
female L. salmonis was higher in the second year than in the first year of production in 
British Columbia (Saksida et al. 2007). In Europe, the highest proportion of gravid 
females on farmed salmon has been reported to occur in the winter months (Tully 1989).   
There are many factors which may contribute to differences in sea lice 
abundance between British Columbia and other regions. Single year class sites are used 
in British Columbia (Saksida et al. 2007), similar to Scotland but different from 
Norway. The water temperatures in the Broughton Archipelago (6.0-13.2°C) are similar 
to those reported in Scotland (5.5-16.2 °C), while temperatures in Norway have a 
greater range (2.5-19.5 °C) (Heuch et al. 2003). There is a larger wild salmon population 
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in British Columbia than in Norway. Norway is considered to have the largest wild 
Atlantic salmon population in Europe (2-2.5 million) (Heuch & Mo. 2001, Irvine & 
Fukuwaka 2011), while the average annual catch for wild Pacific salmon in eastern 
North Pacific Ocean has been well over 100 million per year from 1990 until recent 
years (Irvine & Fukuwaka 2011). It is plausible that returning wild adult salmon may be 
a source of sea lice on farms located in regions with large salmon runs.   
Lees et al. (2008c) reported a notable change in sea lice abundance (L. salmonis 
and C. elongatus), infestation patterns and ectoparasiticide use over the 11-year period 
studied (1996 to 2006, excluding 2001) in Scotland. The study divided sea lice counts 
into two time periods: 1996-2000 and 2002-2006. There was a significant drop in lice 
abundance from the first to second time period with a marked reduction in abundance 
through the summer months of the second production year. This reduction did vary by 
region, with the Western Isles region having significantly higher levels of lice than the 
North. Interestingly, this later time period corresponded to the introduction of the use of 
emamectin benzoate. After the introduction of emamectin benzoate, lice levels dropped 
and were similar to those observed in the Broughton Archipelago in British Columbia 
where this product was also in use.   
Lees et al. (2008c) also found higher levels of C. elongatus on fish during their 
first year at sea compared to second year fish and, during the first year, these were at a 
similar level to mobile stages of L. salmonis. However, during the second year at sea, L. 
salmonis were around eight times more abundant in Scotland. This finding is in contrast 
to Saksida et al. (2007) who found no difference in abundance of C. clemensi on fish 
between first and second years at sea in British Columbia. The reason for this variation 
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could not be determined but species and location differences are two plausible 
explanations. 
Heuch et al. (2009) reviewed Norwegian sea lice (L. salmonis) levels from 2004 
to 2006 and examined factors influencing these levels. They found that salinity, mean 
fish weight, and treatment type were all significantly associated with L. salmonis 
abundance. Similar to Scotland and British Columbia, larger fish had a tendency 
towards higher L. salmonis abundance. Sea lice abundance was lower on sites with low 
WRPHGLXPVDOLQLW\ÅS). Adult female sea lice abundance was significantly 
lower during times when emamectin benzoate was being administered, as opposed to 
other treatment options, which is in agreement with the findings of Lees et al. (2008c). 
Fish treated with emamectin benzoate appeared to have the lowest mean adult female 
lice abundance. A reason for this finding may be the long-lasting effect of this in-feed 
medicine (Stone et al. 2000a). Pyrethroid treatments are applied as bath treatments and 
do not have residual effects to provide the fish with protection much beyond treatment 
application. It is worth mentioning that in Norway, fish in the first year of production 
are generally treated with emamectin benzoate while larger, second year fish are treated 
with pyrethroids. Higher overall lice abundance during the second year of production 
may be a factor in higher lice numbers found on pyrethroid treated fish.  Interestingly, in 
the study by Heuch et al. (2009), untreated fish had lower sea lice abundance than the 
pyrethroid-treated fish. Producers were only asked to administer treatment if fish had a 
total mean abundance above 0.3 adult female lice per fish. The low lice abundance 
recorded on such fish during the subsequent sampling period confirms that farmers were 
correct in their judgement that delousing treatments were not required.  
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There has been limited study of sea lice population trends on farmed Atlantic 
salmon in the Bay of Fundy, Canada. Hogans & Trudeau (1989) examined prevalence 
and intensity of sea lice on farmed salmon by regularly sampling three farm sites in the 
Bay of Fundy from 1988 to 1989. The predominant species at that time was C. 
elongatus accounting for 97.3% of sea lice observed during the study. Two other species 
were noted, L. salmonis and Caligus curtus (rarely found). Prevalence and intensity of 
sea lice were highest during late summer and fall when the water temperatures were the 
warmest (August through November). This peak was thought to be due to the five week 
generation time of C. elongatus since the highest number of chalimus stages was seen in 
the months of August and September. Even in the absence of treatment, there was a 
reduction in prevalence of sea lice during the colder months of December to February 
when water temperatures were lowest. Although only three sites were used in this study, 
researchers found some location differences where the site located in Lime Kiln Bay had 
the highest levels of sea lice infestation of all three sites (the other two sites were in 
Passamaquoddy Bay and near Campobello Island) (see Figure 2.1 on page 57). Water 
temperatures between all three sites were found to be similar; it was postulated that 
other environmental factors may have played a role, such as the enclosed nature of that 
area or the higher density of farm sites.  
A subsequent examination of sea lice populations in the Bay of Fundy was 
instigated when there was a sudden increase in L. salmonis on farmed salmon beginning 
in the fall of 1994 (Hogans 1995). Again, infection intensity was positively correlated 
with water temperature. When water temperatures decreased through the winter months, 
the lice abundance levels decreased as well. They found that market size fish tended to 
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have more sea lice than smolts. At this time, both ivermectin and hydrogen peroxide 
treatments were in use as the heavy sea lice infestations were resulting in damage to the 
fish and subsequent mortalities. Prevalence and intensity of sea lice varied by location 
with the worst of the epidemic occurring in the Lime Kiln and Back Bay areas. 
1.9 Thesis objectives 
1.9.1 Overall goals 
The overall goal of this research was to examine the effectiveness of the clinical 
use of emamectin benzoate against sea lice on farmed Atlantic salmon. Sea lice have 
developed resistance to this agent in various salmon farming regions around the world 
and, more recently, resistance emergence in Atlantic Canada was suspected.  
1.9.2 Specific objectives 
The focus of Chapter 2 was to examine the potentially changing emamectin 
benzoate effectiveness on L. salmonis. The objectives of this retrospective analysis were 
to establish if changes in effectiveness of emamectin benzoate were present from 2004 
to 2008, to examine factors associated with treatment outcome (effective or ineffective), 
and to ascertain which variables influenced differences in post-treatment L. salmonis 
abundance. The area of interest was the Bay of Fundy in the southwestern region of 
New Brunswick, Canada. 
The objectives of Chapter 3 were to determine if there was evidence of a 
temporal pattern to treatment responses that varied across sea lice life stages, and then to 
explore how these differences might be used to improve the monitoring of treatment 
effectiveness in a clinical or field setting. A simple and robust method for monitoring 
treatment effectiveness using field collected data would be beneficial as a tool which 
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could be used in conjunction with bioassays and molecular level tests for resistance 
detection.  Two data sets from two salmon farming regions were examined: New 
Brunswick, Canada, and the west coast of Scotland. 
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Chapter 2 Evaluation of emamectin benzoate effectiveness for treatment of sea 
lice (Lepeophtheirus salmonis) on farmed Atlantic salmon (Salmo salar) in the Bay 
of Fundy, Canada 1 
 
2.1 Abstract 
Emamectin benzoate (an avermectin chemotherapeutant administered to fish as 
an in-feed treatment) has been used to treat sea lice (Lepeophtheirus salmonis) 
infestations on farmed Atlantic salmon (Salmo salar) in the Bay of Fundy, New 
Brunswick, Canada since 1999. This retrospective study examined the effectiveness of 
114 emamectin benzoate treatment episodes from 2004 to 2008 across 54 commercial 
Atlantic salmon farms. Study objectives were to establish whether changes in the 
effectiveness of emamectin benzoate were present for this period, examine factors 
associated with treatment outcome, and determine variables which influenced 
differences in post-treatment L. salmonis abundance. The analysis was carried out in two 
parts: first, trends in treatment effectiveness and L. salmonis abundance were explored, 
and second, statistical modelling (linear and logistic regression) was used to examine the 
effects of multiple variables on post-treatment abundance and treatment outcome.    
Post-treatment sea lice abundance increased in the later years examined. Mean 
abundance differed between locations in the Bay of Fundy, and higher numbers were 
found at farms closer to the mainland and lower levels were found in the areas around 
Grand Manan Island. Treatment effectiveness varied by geographical region and 
decreased over time. There was an increased risk for unsuccessful treatments in 2008 
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and treatments applied during autumn months were more likely to be ineffective than 
those applied during summer months.  
2.2 Introduction 
Sea lice are aquatic ectoparasitic copepods of the family Caligidae, and feed on 
the mucus, skin, and blood of the host fish. While low level infestations of sea lice cause 
only minimal impacts to the host, high numbers can result in progressively worsening 
skin damage and even death of the host. As early as 1940, there were reports of high 
numbers of lice causing severe damage and mortality in wild fish (White 1940). 
Intensive salmon farming, particularly where fish farms are clustered in regions, can 
contribute to outbreaks of pathogens and, potentially, to clinical disease (Murray & 
Peeler 2005, Robertsen 2011). 
Lack of adequate control over sea lice populations can result in a number of 
economic impacts on fish producers.  In addition to mortalities related to sea lice 
infestation and the cost of parasiticides, other factors, such as increased personnel costs, 
reduction in food conversion efficiency, reduced fish growth, and mortalities secondary 
to treatment contribute to economic losses (Costello 2009).  
There are two genera of sea lice commonly found on salmonids in marine and 
brackish waters: Lepeophtheirus and Caligus. Major species associated with salmon 
aquaculture along the east coast of Canada and the United States are Lepeophtheirus 
salmonis and Caligus elongatus (Boxaspen 2006). Lepeophtheirus salmonis is the more 
pathogenic species in the Bay of Fundy, New Brunswick, Canada, mostly due to its size 
and aggressive feeding in the later stages of the life cycle. Lepeophtheirus salmonis has 
a ten-stage life cycle with a moult between each stage. There is a free-swimming phase 
53 
 
consisting of two naupliar and one copepodid stage. The copepodid settles on the host 
fish to begin the attached phase, and will then moult through four chalimus, two pre-
adult and one adult stage (Johnson & Albright 1991a, Schram 1993). Johnson & 
Albright (1991b) reported the generation time to be 40 days for adult males and 52 days 
for adult females at 10°C (time from egg to adult stage) under laboratory conditions.  
Salmon farming is a two phase production system usually consisting of land-
based, fresh-water hatchery and marine cage site phases. Fish are transferred from the 
hatchery as smolts to sea cages, which can occur anywhere from one to two years after 
egg hatching. Fish are harvested approximately 18 to 24 months after transfer to sea 
cages. In New Brunswick, smolts are normally transferred in the spring (April to June) 
or fall (November to December), and the majority of the fish are transferred during the 
spring months.  Sea lice are a problem isolated to the marine stage of the production 
cycle. 
Emamectin benzoate (SLICE®) is an avermectin chemotherapeutant 
administered to fish as an in-feed treatment (reviewed by Horsberg 2012). Emamectin 
benzoate was shown to be effective against L. salmonis on farmed Atlantic salmon in 
North America (Armstrong et al. 2000, Gustafson et al. 2006, Saksida et al. 2007). 
Several studies have examined the efficacy of emamectin benzoate in the United States 
(Maine), Scotland, and Canada (British Columbia) (Gustafson et al. 2006, Lees et al. 
2008a, Lees et al. 2008b, Saksida et al. 2010). In Maine, all treatments that were applied 
appeared to be efficacious; however, the study did not examine for changes in 
effectiveness over the study period of 2002 to 2005 (Gustafson et al. 2006). 
Examination of emamectin benzoate use in British Columbia found no decrease in 
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effectiveness from 2003 to 2008 (Saksida et al. 2010). A decline in efficacy was 
reported in Scotland during the years examined, 2002 to 2006 (Lees et al. 2008a, Lees et 
al. 2008b). On the east coast of Canada, a recent investigation using laboratory 
bioassays found increases in EC50 values for emamectin benzoate in L. salmonis from 
southwestern New Brunswick collected in 2011 (Igboeli et al. 2012) compared with 
values from 2002-2005 (Westcott et al. 2008). A reduction in the sensitivity of Caligus 
rogercresseyi to emamectin benzoate based on laboratory bioassays has been 
documented in Chile (Bravo et al. 2008).  
In New Brunswick, control of sea lice became a problem in the mid ¶VZKHQ
there was a consistent increase in the abundance of sea lice found on farmed Atlantic 
salmon. Initially the majority of sea lice on farmed salmon were Caligus spp., but L. 
salmonis later became the predominant species and remains so to the present (Hogans & 
Trudeau 1989, Hogans 1995). In the fall of 1994, an outbreak of L. salmonis occurred 
on salmon farms in the Lime Kiln and Back Bay areas of southwestern New Brunswick 
(Hogans 1995). Around that time, a multitude of treatments were attempted with varying 
success, including hydrogen peroxide, ivermectin, and azamethiphos (Hogans 1995, 
O'Halloran & Hogans 1996). Emamectin benzoate was introduced in New Brunswick in 
1999 through an emergency drug release (Armstrong et al. 2000). This product became 
the treatment of choice for several reasons: effectiveness against all life stages, 
prolonged effect, and ease of administration in feed (Stone et al. 2000a, Stone et al. 
2000b). Because emamectin benzoate was an effective treatment, there was little 
incentive to seek approval for other sea lice treatment agents, resulting in this product 
being used for the majority of sea lice treatments. After almost a decade of use, isolated 
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treatment failures were observed in late 2008, resulting in suspicions about changes in 
sea lice sensitivity to emamectin benzoate. During 2009, it became evident that a more 
serious problem was occurring, which compelled industry and government to investigate 
other methods of treatment for sea lice (Chang et al. 2011). 
The focus of the present study was to examine emamectin benzoate treatment 
effects on L. salmonis. The objectives of this retrospective analysis were: (1) to establish 
whether changes in effectiveness of emamectin benzoate were present from 2004 to 
2008, (2) to examine factors associated with treatment outcome (effective or 
ineffective), and (3) to ascertain which variables influenced differences in post-
treatment L. salmonis abundance. A cross-section of data obtained from health records 
collected by salmon farms in the Bay of Fundy region of southwestern New Brunswick, 
Canada, from 2004 to 2008 was examined.   
2.3 Materials and methods 
The Bay of Fundy is located on the east coast of Canada between New 
Brunswick and Nova Scotia and shares water with Cobscook Bay, Maine, USA (Figure 
2.1). The area of interest for this study was along the New Brunswick coast of the Bay 
of Fundy where farming of Atlantic salmon represents a major aquaculture activity. A 
bay management system is used for the location and stocking of fish farms, called 
Aquaculture Bay Management Areas (ABMA). Figure 2.1 shows the eight ABMAs as 
they were established in 2006. In 2010, ABMA 4 was incorporated into ABMA 1, and 
for the purpose of this study that change was used for all years examined. Data were 
available from five ABMAs (Table 2.1):  1, Passamaquoddy Bay (including sites around 
Deer Island and Campobello Island); 2a, Lime Kiln Bay and Back Bay; 3a, which is 
56 
 
FRQVLGHUHGWKH³XSVKRUHUHJLRQ´KHDGLQJHDVWWRZDUGV6DLQW-RKQ(including areas such 
as Beaver Harbour and Maces Bay); and 2b and 3b, which are both located on the 
eastern side of Grand Manan Island. These five ABMAs contained the majority of active 
salmon farms. There were no qualifying treatment episodes in ABMAs 5 or 6, but since 
only a few active salmon farms were present in these areas; this was not expected to 
KDYHDQLPSDFWRQWKLVVWXG\¶VFRQFOXVLRQV)RUSDUWRIWKLVDQDO\VLVi.e. statistical 
models), ABMAs 2b and 3b, which are located around Grand Manan Island, were 
grouped together because they are adjacent to each other and relatively far removed 
from the other ABMAs. 
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Figure 2.1  Aquaculture Bay Management Areas (ABMAs) for the southwestern New 
Brunswick Bay of Fundy salmon farming region (salmon farm leases for 2010 are 
indicated).   
 
Note:  Map kindly provided by Blythe Chang of the Department of Fisheries and Oceans 
Canada, St. Andrews Biological Station, St. Andrews, New Brunswick, Canada. 
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Table 2.1  Summary of qualifying emamectin benzoate treatment episodes that occurred 
in each Aquaculture Bay Management Area (ABMA) of the Bay of Fundy (2004-2008). 
ABMA (Location) Number of Qualifying 
Treatment Episodes 
Effective Treatments 
(%) 
1 (Passamaquoddy Bay & 
Deer/Campobello I.) 
46 38 (82.6%) 
2a (Lime Kiln, Back Bay) 26 16 (61.5%) 
2b (Grand Manan Island) 7 7 (100.0%) 
3a (Maces Bay) 20 18 (90.0%) 
3b (Grand Manan Island) 15 15 (100.0%) 
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The data used in this study were extracted from records collected and maintained 
for sea lice management purposes by the veterinary services within Cooke Aquaculture 
Inc. (Blacks Harbour, New Brunswick) and Maritime Veterinary Services Ltd. (St. 
Andrews, New Brunswick). These records were associated with just over half of the fish 
farming sites and the majority of the companies operating in this region for the period 
under examination.   
Regular sea lice counts are a routine part of salmon farming in this region, as 
they are for most salmon farming areas around the world, with counts typically 
occurring at least once every second week. A number of fish are opportunistically 
sampled by attracting them to the water surface with feed and capturing them with a 
hand net. Typically fish are anesthetized in a water bath with tricaine methanesulfonate 
added, and when sufficiently immobilized, the sea lice are counted and classified by 
using the following life stages: chalimus, pre-adult females, pre-adult males, adult males 
and adult females (gravid and non-gravid). However, pre-adult males and pre-adult 
females are often combined with adult males in records to form one category. In this 
particular study, we examined only L. salmonis as this is the more pathogenic and far 
more prevalent species on farmed Atlantic salmon in the Bay of Fundy (Hogans 1995).  
The study design and methodology used in this investigation was similar to 
methods used in Lees et al. (2008a, 2008b) in Scotland. Historical sea lice count data 
and treatment records were examined from 2004 to 2008 and treatment episodes were 
selected based on specific study inclusion criteria. In order to be included, a treatment 
episode had to contain a pre-treatment count within 16 days of treatment being started, 
as well as a minimum of three post-treatment sea lice evaluations in the 12 weeks 
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following initiation of treatment. If there was more than one pre-treatment count 
available in the 16 day period, then the count closest to the date of treatment initiation 
was used. A specific sea lice count was only included when at least two cages were 
sampled and a minimum of five fish per cage were examined. Treatment of sea lice with 
emamectin benzoate involves the administration of medicated fish feed over the course 
of seven days. Any treatment that had a notation in the record regarding only partial site 
treatment or split site treatment was excluded from this analysis. For this analysis, pre-
adult males, adult males, pre-adult females and adult females (gravid and non-gravid) L. 
salmonis were aggregated into a single group called µtotal mobiles¶.  
The analysis was split into two parts: first, description of treatment efficacy and 
trends in L. salmonis abundance, and second, statistical modelling (linear and logistic 
regression) to examine the effects of multiple variables on post-treatment mean mobile 
L. salmonis abundance and treatment outcome. For the former, treatment trends were 
summarized at the farm level and examined by year in two ways: mean abundance of 
total mobiles before and after treatment, and treatment effectiveness as a percentage of 
the pre-treatment abundance. Pre-treatment mean abundance of mobile L. salmonis 
varied by year and this variance was examined by use of an ANOVA procedure. For 
comparisons of means, a post-ANOVA multiple comparisons procedure was performed 
using the Bonferroni method. Treatment effectiveness was determined by the following 
equation: Treatment effectiveness = (post-treatment mean abundance/ pre-treatment 
mean abundance) * 100%. A treatment was considered effective if post-treatment mean 
abundance fell to less than 40% of the pre-treatment mean abundance at any point 
during the post-treatment period. This value has been used in previous articles as a cut-
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off point upon which to base treatment success with emamectin benzoate (Lees et al. 
2008a, Lees et al. 2008b, Saksida et al. 2010). 
The second part of the analysis involved the building of two statistical models: a 
linear model for post-treatment mean mobile L. salmonis abundance, and a logistic 
model of treatment effectiveness. Predictor variables used in the building of the 
statistical models were year, pre-treatment mean mobile L. salmonis abundance, location 
of farm (ABMA), season, month, season2 (see below), age of fish, and season of smolt 
transfer, as well as the week of count during the post-treatment period. Fish were 
classified into first or second production year based on the age of fish since smolt 
transfer to ocean cages. Fish were classified as first year fish if they had been at sea for 
less than 365 days and as second year fish if they were at sea for more than 365 days. 
Fish were also classified into groups based on the season of smolt transfer, either spring 
or autumn. Given that temperature and season can be important factors in relation to sea 
lice abundance, the variables month, season and season2 were created to examine their 
potential impact on post-treatment L. salmonis abundance. The month of treatment 
application was used as a predictor, along with a season variable created by categorizing 
months into the following groups: spring (April-June, 4-9 °C), summer (July-September, 
11-14 °C), autumn (October-November, 8-11 °C), and winter (December-March, 1-7 
°C). Water temperatures tend to be highest in August-September (12-14 °C) and lowest 
in February-March (1-2 °C). Thirdly, a variable, called season2, was created where 
season was dichotomized based on months where water temperatures were generally 
above or below 10 °C. Water temperatures were generally above 10 °C from July to 
October and below 10 °C from November to June. For the variable week, the baseline 
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value was week 2, corresponding to days 7 to 13 after the start of treatment. Week 1 was 
eliminated from this part of the analysis because there was usually no noticeable 
treatment effect at this point (often there was an increase in L. salmonis abundance, as 
noted in Figure 2.2). As mentioned above, for both statistical models, the Grand Manan 
Island ABMAs 2b and 3b were grouped together (Figure 2.1). 
For the linear model, upon initial examination of the outcome variable (mean 
abundance of total mobiles), the data was found to be positively or right-skewed. A 
Box-Cox analysis produced a lambda value of 0.087. This led to logarithmic 
transformation of the data by [ln(mean + 0.1)] to help improve our statistical 
assumptions of normality of residuals and homoscedasticity. Pre-treatment abundance 
was also logarithmically transformed. Predictor variables were initially screened 
unconditionally, with those having a p-value <0.15 retained for model building. The 
linearity of the relationship between pre-treatment and post-treatment (log) counts was 
evaluated using a locally weighted scatterplot smoothing algorithm (Lowess) and found 
to be acceptable. Initially, both treatments and farms were considered random effects, 
but little unexplained variation was found at the farm level; therefore, a two level model 
(sampling weeks within treatment episodes) was constructed. A Toeplitz covariance 
structure to account for correlations among counts up to six weeks apart was applied at 
the lowest (week) level. Model building was carried out manually with interactions 
among key variables evaluated as part of the process. Residuals at both the week and 
treatment episode level were checked for normality and homoscedasticity.  
The second model was a logistic regression model used to evaluate factors 
associated with treatment success or failure. Success was defined as a minimum of a 
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60% reduction in L. salmonis burdens at any point in the post-treatment period. The 
outcome variable was treatment success or failure. The predictor variables considered 
were year, month, season, season2, location (ABMA), fish age, season of smolt transfer, 
and pre-treatment mean L. salmonis abundance (log transformed).  A multilevel logistic 
model using treatments nested within farms was initially assessed but there was little 
unexplained variation between farms; therefore, a simple logistic regression model was 
used.  
A similar model building process to the linear mixed model was used to create 
the logistic regression model. The fit of the final model was evaluated using Hosmer-
Lemeshow goodness-of-fit test. Specific observations not fitting the model or having 
undue influence on the model were evaluated by generating Pearson and deviance 
residuals and any outlying values were examined. Influence of outliers on the model was 
evaluated by generating leverage and delta-beta values. 
Software programs used to analyze data were Microsoft Excel 2007 (Microsoft 
Canada Co., 1950 Meadowvale Blvd., Mississauga, Ontario, Canada) and Stata/IC 12 
(StataCorp LP, 4905 Lakeway Drive, College Station, Texas, USA). Microsoft Excel 
2007 was used to manage and format the data, and to create the mean abundance and 
efficacy graphs. Stata 12 was used to perform the trend and efficacy analysis along with 
the statistical models. 
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2.4 Results  
After excluding treatment episodes based on study inclusion criteria, 114 
treatment episodes across 54 farms remained in this analysis. There was a mean of 40 
fish examined per sample (range 10-240) and 4.3 cages selected per sample date (range 
1-19).  
2.4.1 Trends in abundance and effectiveness 
The pre-treatment mean abundance of mobile L. salmonis varied over the five 
years examined.  In 2004, pre-treatment mean abundance was 0.7 mobiles per fish and 
increased annually to around ten times this value by 2007 and 2008 (Figure 2.2 & Table 
2.2). Based on an ANOVA procedure, year had significant (p < 0.01) influence on pre-
treatment abundance. Bonferroni multiple-comparisons determined that there were 
significant differences in pre-treatment means between years 2004 and 2007 (p=0.001), 
2004 and 2008 (p=0.001), as well as between 2005 and 2008 (p=0.035). The difference 
between 2005 and 2007 was marginally significant at p=0.056. 
Table 2.3 lists the number of treatments per year as well as classifying treatments 
by success or failure. If the post-treatment mean abundance of L. salmonis fell to less 
than 40% of the pre-treatment value at any point during the follow-up period, then an 
individual treatment episode was deemed effective. Effectiveness could not be 
calculated for episodes where pre-treatment abundance was zero and this occurred in 
two treatment episodes, one from 2004 and another from 2008. Both of the treatments 
resulted in very low L. salmonis abundance in the follow-up period, with a range of 0-
0.07 mobiles per fish in all weeks; therefore, these treatments were classified as 
successful.
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Figure 2.2  Mean abundance (+/- SE) of mobile Lepeophtheirus salmonis pre- and post-
treatment with emamectin benzoate on farmed Atlantic salmon in New Brunswick, 
Canada (2004-2008).  
  
0
2
4
6
8
10
M
ea
n
 a
bu
n
da
n
ce
 m
o
bi
le
 li
ce
 (+
/-S
E)
 
Weeks after treatment 
2004
2005
2006
2007
2008
66 
 
Table 2.2:  Mean abundance (+/- SE) of mobile Lepeophtheirus salmonis pre- and post-
treatment with emamectin benzoate on farmed Atlantic salmon in New Brunswick, 
Canada (2004-2008).  
Week 2004 2005 2006 2007 2008 
 
     
Pre-Tx 0.70 (0.39) 1.60 (0.30) 2.58 (0.54) 8.68 (2.05) 6.34 (1.14) 
1 0.28 (0.17) 2.13 (0.82) 4.65 (1.04) 8.41 (2.12) 8.31 (1.88) 
2 0.38 (0.24) 1.33 (0.52) 3.23 (1.12) 8.06 (2.17) 7.41 (1.27) 
3 0.05 (0.03) 0.34 (0.11) 0.90 (0.21) 4.74 (1.92) 5.42 (1.16) 
4 0.02 (0.02) 0.20 (0.10) 0.49 (0.10) 2.76 (0.79) 7.24 (1.53) 
5 0.07 (0.06) 0.15 (0.07) 0.21 (0.05) 1.28 (0.34) 5.98 (1.48) 
6 0.01 (0.01) 0.11 (0.05) 0.24 (0.15) 1.11 (0.29) 6.06 (2.12) 
7 0.14 (0.08) 0.04 (0.03) 0.29 (0.10) 1.36 (0.46) 4.13 (1.32) 
8 0.02 (0.02) 0.14 (0.06) 0.30 (0.08) 2.39 (1.05) 3.95 (1.52) 
9 0.01 (0.01) 0.21 (0.09) 0.41 (0.13) 4.28 (2.51) 6.11 (1.62) 
10 0.74 (0.54) 0.49 (0.29) 1.61 (0.54) 4.49 (2.65) 5.85 (1.83) 
11 0.11 (0.11) 1.01 (0.42) 2.99 (1.08) 3.36 (1.35) 5.55 (1.82) 
12 0.26 (0.26) 0.72 (0.46) 1.26 (0.99) 3.32 (1.77) 4.86 (2.18) 
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Table 2.3  Summary of qualifying emamectin benzoate treatment episodes by year and 
number of treatments which were effective (percentage of effective treatments) or 
ineffective. 
Year Number of 
Qualifying 
Treatment 
Episodes 
Number of Effective 
Treatments (<40% of pre-
treatment mobile L. 
salmonis abundance) 
Number of 
Ineffective 
Treatments 
2004 7 7 (100.0%) 0 
2005 20 20 (100.0%) 0 
2006 23 22 (95.6%) 1 
2007 31 28 (90.3%) 3 
2008 33 17 (51.5%) 16 
Total 
Treatment 
Episodes 
114 94 (82.5%) 20 
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Treatment effectiveness declined through the years examined. In 2004 and 2005, 
all treatments evaluated were deemed effective, while through 2006 to 2008, the number 
of ineffective treatments progressively increased each year. In 2006, the first ineffective 
treatment was noted and two other treatment episodes were marginally effective, where 
the maximum effectiveness was 36.9% and 33.7% of the mean pre-treatment abundance. 
Maximum effectiveness was determined using the lowest percentage attained during the 
post-treatment period. Overall, 94 of 114 treatment episodes or 82% were classified as 
effective for all the years examined. The major change occurred between 2007 and 2008 
when the percentage of successful treatments decreased from 90% to 51%. 
In 2007, 28 of 31 treatments were deemed effective in this study, though only 20 
treatments reached a post-treatment abundance level of <1 mobile per fish. In 2008, 17 
of the 33 treatments were considered effective based on the cut-off point of 40%; 
however, only 14 of these treatments reached post-treatment abundance of <1 mobile 
per fish.   
Figure 2.3 demonstrates the effectiveness of emamectin benzoate summarized by 
year as a percentage of pre-treatment mean abundance of L. salmonis. All years, on 
average, exhibited overall treatment success, except for 2008. However, the maximum 
level of effectiveness attained decreased with each subsequent year. In 2004, post-
treatment mean abundance fell to as low as 0.9% of pre-treatment levels during the 
follow-up period, while in 2005, maximum effectiveness was 6.8% of the pre-treatment 
level and this effectiveness continued to erode over the next three years (15.3% for 
2006, 22.6% for 2007 and 75.7% for 2008).   
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Duration of treatment effect varied between treatment episodes, but in this study 
it appeared to last approximately nine to ten weeks during the early years (Figure 2.3). 
In 2004 and 2005, the trends were typical for an effective treatment with emamectin 
benzoate when the percentage of pre-treatment levels decreased to less than 20% by 
week 3 and remained relatively low for the following seven weeks. In 2006, there was 
an expected drop in mobile L. salmonis numbers following treatment, but effectiveness 
values did not stay low for as long as those seen in 2004 and 2005 as evidenced by an 
increase which began around week 8, after two to three weeks of minimum values. By 
2007, there appeared to be a steady rise in values beginning around week 6 or 7 after 
treatment. The dramatic drop previously observed in the first few weeks following 
treatment was absent in 2008. Although just over 50% of treatment episodes were 
deemed effective, treatments as a whole for that year were classified as ineffective, this 
is evident in the failure to drop below 75% in 2008 (Figure 2.3). Overall, duration of 
treatment effect appeared to decrease with time. 
Time to maximum effectiveness varied by treatment episode and year. In the 
early years, maximum treatment effect was generally attained between weeks 4 and 6 
following the start of treatment (Figure 2.3). The time to maximum effect was extended 
to week 7 in the final year of the study (2008).
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Figure 2.3  Trends in treatment effectiveness (as a percentage of pre-treatment mean 
abundance of mobile Lepeophtheirus salmonis) of emamectin benzoate treatments 
against L. salmonis on farmed Atlantic salmon in New Brunswick, Canada (2004-2008).  
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2.4.2 Statistical modelling of post-treatment sea lice abundance 
The linear mixed model was evaluated initially using a three level model with 
weeks nested within treatments and treatments nested within farms. There were 114 
treatments spread over 54 farms resulting in a mean of 2.1 treatments per farm (range 
was 1 to 5). We determined that the use of farm as a random effect was not necessary 
given there was little unexplained variation at the farm level, likely resulting from the 
fact that there were so few treatments per farm. As a result, a two level model was used 
with weeks nested within treatments. Treatment episodes were treated as random 
effects. In the two level model, there was little unexplained variation at the treatment 
level as all the variation was explained by both the fixed parameters and the unexplained 
variation by the covariance pattern (Toeplitz correlation structure) at the lowest level 
(week). The covariance estimates confirmed that there was a high level of correlation 
among counts collected close together (one to two weeks apart), but that this declined 
steadily and there was no remaining correlation once counts were more than six weeks 
apart.  
Results of the linear mixed model are shown in Table 2.4 as the log transformed 
values. Post-treatment mean L. salmonis abundance increased during the later years of 
the study with significant differences found between 2004 and 2007, and between 2004 
and 2008. No significant differences were found between post-treatment L. salmonis 
levels in ABMA 1 (Passamaquoddy Bay) and 2a (Lime Kiln Bay) or 1 and 3a (Maces 
Bay). Significantly lower levels of L. salmonis abundance were found at sites near 
Grand Manan Island (ABMAs 2b and 3b) compared to sites in Passamaquoddy Bay 
(ABMA 1).   
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Pre-treatment mean L. salmonis abundance was a significant predictor in the 
level of abundance during the post-treatment period. For every increase in the pre-
treatment abundance of 1 natural log value (equivalent to an increase by a factor of 2.7 
times), there was a corresponding increase in the post-treatment log-values of 0.44 
(equivalent to an increase by a factor of ~1.5 times).  
There was a significant interaction between age of fish and season of smolt 
transfer indicating that the effects of fall transfer were different in second year fish 
compared to first year fish. Ultimately, fish in their second year and transferred to 
seawater in the fall were more likely to have higher post-treatment L. salmonis 
abundance than second year fish which were transferred in the spring.   
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Table 2.4  Results of the linear mixed regression model of mean mobile Lepeophtheirus 
salmonis abundance (log transformed) following treatment with emamectin benzoate at 
Atlantic salmon farms in New Brunswick, Canada, for 2004-2008. (Baseline values are 
year=2004, bay code=Passamaquoddy, season of transfer=spring, fish age= <1 year, 
week=2). 
 
Variable Category 
Coefficient 
(log 
transformed) 
SE p-
value 
95% Confidence 
Interval 
 
    Lower Upper 
Year 2005 0.10 0.32 0.759 -0.53 0.73 
 
2006 0.30 0.32 0.354 -0.33 0.93 
 
2007 0.86 0.33 0.010 0.21 1.51 
 
2008 1.60 0.34 0.000 0.94 2.26 
Bay code (ABMA) Lime Kiln (2a) -0.41 0.24 0.087 -0.87 0.06 
 
Grand Manan 
(2b & 3b) -1.09 0.18 0.000 -1.45 -0.73 
 
Maces Bay (3a)  -0.38 0.20 0.061 -0.78 0.02 
Week 3 -0.66 0.07 0.000 -0.81 -0.52 
 
4 -0.90 0.09 0.000 -1.08 -0.72 
 
5 -1.15 0.10 0.000 -1.36 -0.95 
 
6 -1.22 0.12 0.000 -1.46 -0.97 
 
7 -1.23 0.13 0.000 -1.48 -0.98 
 
8 -1.07 0.14 0.000 -1.34 -0.80 
 
9 -0.80 0.15 0.000 -1.09 -0.51 
 
10 -0.46 0.15 0.000 -0.76 -0.16 
 
11 -0.26 0.16 0.111 -0.57 0.06 
 
12 -0.07 0.18 0.686 -0.43 0.28 
Season of transfer  Autumn  0.16 0.28 0.572 -0.39 0.70 
Fish age >365 days 0.28 0.16 0.076 -0.03 0.60 
Fish age x season of 
transfer interaction 
 0.84 0.32 0.009 0.21 1.47 
Pre-treatment 
abundance 
(log transformed) 
 
0.44 0.06 0.000 0.32 0.55 
Constant  -0.42 0.33 0.200 -1.06 0.22 
Random Effects 
Parameters 
 Estimate SE  95% Conf Interval 
Treatment: Identity Variance 
(constant) 1.26 x 10
-15
  
   
Residual: Covariance1 0.76 0.07 
 
0.62 0.91 
Toeplitz (6) Covariance2 0.61 0.07  0.48 0.74 
 
Covariance3 0.47 0.06 
 
0.35 0.58 
 
Covariance4 0.30 0.05 
 
0.20 0.39 
 
Covariance5 0.22 0.04 
 
0.14 0.29 
 
Covariance6 0.10 0.03 
 
0.05 0.15 
 
Variance (e) 0.98 0.07 
 
0.84 1.14 
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2.4.3 Statistical modelling of treatment outcome 
A logistic regression model examined factors involved with treatment outcome, 
classified as either effective or ineffective treatments (Table 2.5). Given that there were 
no ineffective treatment episodes found in either 2004 or 2005, those years were 
dropped from this component of the analysis. The spring season was also dropped as it 
contained only four treatment episodes (one in 2006 and three in 2008), none of which 
were classified as ineffective. Based on the exclusion of the episodes from these years 
and season, a total of 83 treatment episodes were evaluated, which led to a mean of 1.8 
treatments per farming site.  
Location of treatment was not significant in the full model. However, the model 
was unable to estimate the effect of predictor variables on treatment failure in ABMAs 
2b or 3b (Grand Manan Island) as there were no failed treatments in the data set, even in 
2008. There appeared to be no significant differences in treatment outcome between 
ABMAs 1, 2a, and 3a.  All possible interactions between variables were evaluated 
during the model building process and none were found to be significant. Fit of the 
model to the data was evaluated by use of the Hosmer-Lemeshow goodness-of-fit test; 
there was no evidence of lack of fit. All potentially influential observations or outliers 
were assessed and examined, and none were found to have undue influence on the 
model. 
In summary, this model showed that treatments applied in 2008 had an increase 
in the odds of failure by 37 times over a treatment applied in the year 2006. Season was 
also a significant variable (p<0.01); treatments administered during autumn (October-
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November) had an odds of failure approximately seven times that of treatments applied 
during summer months (July-September).   
76 
 
Table 2.5  Results of logistic regression analysis of factors associated with ineffective 
emamectin benzoate treatments at salmon farms in New Brunswick, Canada, for 2006-
2008. (Baseline value is year 2006 in the summer season). 
 
Variable Category Coefficient SE p-
value 
Odds 
Ratio 
95% Confidence 
Interval 
 
     Lower Upper 
Year 2007 1.02 1.23 0.407 2.78 0.25 31.22 
 
2008 3.63 1.18 0.002 37.64 3.72 380.22 
Season Autumn 1.97 0.74 0.008 7.18 1.67 30.92 
Pre-treatment 
abundance [ln 
(x+0.1)] 
 -0.24 0.26 0.357 0.79 0.47 1.31 
Constant   -3.91 1.15 0.001    
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2.5 Discussion 
There are challenges commonly encountered when using historical production 
data, some of which were reviewed by Lees et al. (2008a). The challenges encountered 
in the current study were that numerous individuals carried out the sea lice counts (lack 
of consistency), pre-treatment counts occurred any time within 16 day period prior to 
treatment initiation (true pre-treatment levels at treatment initiation may have been 
higher than indicated), and treatment episodes were excluded which did not meet the 
inclusion criteria. The use of a large data set helped to improve the statistical power of 
this study.  The data set used in the present study was comparable in size to that used by 
Lees et al. (2008a, 2008b), but larger than those used in similar previously published 
studies (Gustafson et al. 2006, Saksida et al. 2010). 
A concern with the use of historical data is the lack of control groups as 
discussed in Gustafson et al. (2006). Classic assessment of treatment efficacy involves a 
study design in which the effect of treatment is based on the differences between two 
groups randomized to treatment or control, such as attempted by Campbell et al. (2006). 
In the treatment of parasite populations in the aquatic environment where disease 
progression is best controlled while in the early stages, there are animal welfare 
concerns when leaving cages of fish untreated with a growing sea lice infestation. To 
assess the treatment effectiveness of emamectin benzoate in a clinical environment that 
was not amenable to the inclusion of untreated control cages, treatment effects had to be 
based on the change in sea lice populations after treatment compared to the pre-
treatment sea lice assessments. 
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This study relied on sea lice count data recorded by the fish farmers whose 
routine management required frequent enumeration of sea lice on Atlantic salmon. 
Although fish are obtained using non-random samples (i.e. attracting fish to the surface 
with feed and then capturing them with a hand net) and sampling bias may have been 
introduced, there are no practical solutions for frequent random samples in the salmon 
farming environment. Sampling practices have been reviewed in a number of studies 
(Revie et al. 2005, Revie et al. 2007, Heuch et al. 2011) and can be an accurate method 
for detection of farm level sea lice infestations. In field observational studies of sea lice 
patterns, any selection bias associated with estimates of the true mean sea lice 
abundance is assumed to be present in similar levels across different treatment events 
and thus inconsequential to the interpretation of effectiveness.   
In this study, pre-treatment L. salmonis abundance in the early years was lower 
than the pre-treatment abundance in similar studies. In Lees et al. (2008a), the pre-
treatment mean L. salmonis abundance ranged from approximately 5 to 15 mobiles per 
fish, while in Saksida et al. (2010) the range was from approximately 4 to 7 mobiles per 
fish. In the present study, pre-treatment values were, on average, fewer than 3.0 mobiles 
per fish for 2004-2006, but in 2007 and 2008 they rose to 8.7 and 6.3 mobiles per fish 
respectively (Table 2.2). The reason for this change in pre-treatment L. salmonis 
abundance between 2004-2006 and 2007-2008 cannot be determined with this study 
design. This observation may be associated with increased L. salmonis tolerance for 
emamectin benzoate (unable to maintain sufficient control over populations), natural 
variation in the levels of L. salmonis found on farmed fish in that region, or a tendency 
by farm management to initiate treatment decisions differently. Lees et al. (2008a) also 
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observed differences in pre-treatment abundance between years with higher abundance 
occurring in 2003 and 2004.  
During the early years of the present study, duration of treatment effect appeared 
to last for approximately nine to ten weeks following treatment initiation. 
Comparatively, Lees et al. (2008a) found the lowest L. salmonis abundance between 
days 21 and 62 (weeks 4 and 9), with levels generally remaining below pre-treatment 
levels for the full observation period (83 days). We found the length of treatment effect 
was reduced in later years. Development of tolerance in L. salmonis to this compound 
may have been a factor, but one cannot rule out other possible variables, such as 
increases in external infection pressure, seasonal effects, or lack of data in the later 
weeks of some treatment episodes. Recent laboratory bioassay evidence is suggestive of 
the development of decreased sensitivity to emamectin benzoate in L. salmonis from the 
Bay of Fundy over time (Igboeli et al. 2012). In British Columbia, an assessment of 
emamectin benzoate effectiveness found that acceptable levels of post-treatment 
abundance were maintained for at least three months following treatment, with L. 
salmonis levels remaining significantly below pre-treatment levels, as well as staying 
below the 3 mobile L. salmonis trigger level that is used in British Columbia (Saksida et 
al. 2010). The reason for this continued success of emamectin benzoate treatments in 
British Columbia is unknown, but may be influenced by the large populations of wild 
Pacific salmon which may act as a refuge for sea lice sensitive to emamectin benzoate. 
In addition, there are differences in how farms are distributed between these areas; farms 
in British Columbia are located over a larger area, while in southwestern New 
Brunswick, farms are more densely concentrated in a smaller region. These differences 
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may play a role in the variation of L. salmonis sensitivity between these two regions and 
warrants further investigation. 
Results for time to maximum effectiveness were similar to those in other studies. 
In Lees et al. (2008a), the lowest levels were found around the days 28-34 (week 5) in 
the early years of the study, while Gustafson et al. (2006) found similar range of 21-28 
days (week 4) for the maximum effect to be reached. Maximum effectiveness was, on 
average, attained between weeks 4 and 6 from 2004 to 2007. In 2008, maximum 
treatment effect was not evident until week 7 (75.7%). These trends were supported by 
clinical observations that L. salmonis were remaining on fish longer following treatment 
administration when suspicions of tolerance development first emerged (M. Moore, 
personal communication, 2011). 
The major finding from the linear mixed model for variables associated with 
post-treatment mean abundance of L. salmonis was that treatment effect varied both 
temporally and spatially. Post-treatment abundance increased from 2004 to 2008. In 
addition, there were differences by location, and the areas farthest from the mainland at 
Grand Manan Island (ABMAs 2b and 3b) had the lowest L. salmonis burdens. Similar 
findings were reported by Lees et al. (2008a) in Scotland. Variables related to month or 
season of treatment application were non-significant. The majority of treatment episodes 
(97 of 114) in this analysis occurred between July and October; consequently there were 
insufficient treatment episodes spread throughout the year to support conclusions on the 
effects of season on post-treatment abundance. Only one treatment met the inclusion 
criteria during the winter season (December-March) and this was an effective treatment 
in 2004. One could speculate that we would expect to see overall lower L. salmonis 
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abundance around treatment episodes during the winter months as sea lice levels in New 
Brunswick tend to be lowest throughout the winter months (Chang et al. 2011). 
However, time to maximum treatment effect may be delayed in winter as was shown in 
an efficacy study on emamectin benzoate that found treatments applied during colder 
months took longer to reach maximum effect (Stone et al.  2000c). In comparison, Lees 
et al. (2008a) found some seasonal variations in Scottish data in which treatments 
applied during winter (Nov-Jan) and spring (Feb-Apr) had higher post-treatment 
abundance of L. salmonis. 
The frequency of treatments in young versus older fish was almost equivalent 
with 59 treatments being administered to fish less than one year in sea cages and 55 
treatments applied to fish having been in sea water for more than one year. In New 
Brunswick, the majority of smolts are transferred in spring as opposed to fall, and this 
was reflected in the data. Eighty-eight of the 114 treatments were applied to spring 
transferred fish. In our analysis, the quantity of post-treatment L. salmonis abundance in 
second year fish depended upon whether these fish were transferred in spring or fall. For 
example, in 2008, second year fish had a notable increase in modelled post-treatment 
abundance between spring and fall transfers which went from 1.9 to 5.3 mobile L. 
salmonis per fish (for the sixth week following treatment initiation in year 2008 in 
Passamaquoddy Bay). There may be other explanatory factors contributing to the 
significance of this interaction which have not been explored in this study, such as the 
use of emamectin benzoate in the fresh water hatchery phase prior to transfer, proximity 
of other farms treating for sea lice, variation in fish size, or the inability to administer 
treatments due to inclement weather. A linear regression model was also used by Lees et 
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al. (2008a) who similarly found that post-treatment L. salmonis abundance was higher in 
second year fish.  In general, L. salmonis abundance can be higher during the second 
year of production at sea (Lees et al. 2008c, Saksida et al. 2007).  
In the logistic model, pre-treatment L. salmonis abundance was forced into the 
model due to the potential of being a confounding variable. However, pre-treatment 
abundance was found to be non-significant, indicating that pre-treatment levels did not 
appear to be a determining variable for treatment outcome. If a treatment was going to 
be unsuccessful, it was going to happen regardless of L. salmonis abundance prior to 
treatment application. A similar result was found by Lees et al. (2008b) when they 
examined the Scottish data.  Likewise, Lees et al. (2008b) found year and season to be 
significant variables in the logistic model with an increased risk of ineffective treatments 
occurring with time and the most marked increase was noted for the last year examined 
(2006) in the Scottish data. In New Brunswick, a notable increase in risk of failed 
treatments occurred in the last year of the study (2008). Furthermore, autumn treatments 
were at significant risk of failure compared with treatments applied during the summer 
months. Again, there were insufficient data available to evaluate the effects of season on 
treatments applied during winter or spring months.   
This study found that ineffective treatments occurred in all bays except those 
around Grand Manan Island (ABMAs 2b and 3b). Grand Manan Island is located 32 km 
south of Blacks Harbour, New Brunswick. The closest mainland is the easternmost point 
of Maine in the United States, close to the town of Lubec, which is 15 km across the 
Grand Manan Channel (see Figure 2.1). Given the location, sea farms in this area would 
be more exposed to the open ocean than other locations closer to the New Brunswick 
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mainland. These fish are exposed to different environmental variables (farm density, 
tidal excursion, current speeds) which may have resulted in lower sea lice infection 
pressure than fish on farms close to the New Brunswick mainland (Chang et al. 2011). 
Farms in this region are physically farther away from farms closer to the mainland and 
perhaps the resistant sea lice had not migrated that far between farms, or resistance had 
not yet developed locally from repeated treatments leading to selection of emamectin 
resistant sea lice. There were more qualifying treatment episodes on farms located in 
bays closer to mainland New Brunswick (ABMA 1 + 2a = 72 treatments versus ABMA 
2b + 3b = 22). Because there were fewer treatments applied around Grand Manan 
Island, there may have been decreased selection pressure (i.e. selection of resistant sea 
lice) in comparison with other areas. Increased frequency of pesticide application is one 
of the factors associated with parasiticide resistance development (Denholm et al. 2002).   
The underlying cause of ineffective treatments cannot be determined from this 
analysis. In the available treatment records reviewed for this study, emamectin benzoate 
was found to account for > 95% of sea lice treatments applied from 2004 to 2008. 
Although resistance to emamectin benzoate could be the primary cause for treatment 
failure, other reasons for reduced treatment efficacy, such as poor feed ingestion by fish, 
improper application (not feeding for full seven days or missed treatment days due to 
inclement weather), or inappropriate concentration or distribution of the drug within the 
feed may all contribute to subtherapeutic dosing and potentially lead to isolated 
treatment failures. Treatment failures can lead to erroneous conclusions of resistance 
development. In an effort to substantiate suspicions of a decay in treatment 
effectiveness, this study employed epidemiological principles and a relatively large 
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sample size encompassing both time and location to investigate this issue. Evidence 
presented in this study shows a decline in treatment effectiveness with emamectin 
benzoate which is suggestive of resistance development.  
Changes in susceptibility of sea lice to emamectin benzoate have been assessed 
by other methods, of which the most common approach is the bioassay.  Bioassays have 
been used in New Brunswick, Canada (Westcott et al. 2008), as well as in other salmon 
farming regions around the world for monitoring sea lice sensitivity to therapeutic 
agents (Sevatdal & Horsberg 2003, Sevatdal et al. 2005, Bravo et al. 2008). Westcott et 
al. (2008) examined L. salmonis sensitivity to emamectin benzoate by bioassay from 
2002 to early 2005 in samples collected in New Brunswick and found no changes 
between regions or over time by year. There were indications of decreased sensitivity of 
L. salmonis to emamectin benzoate during the fall and winter seasons. More recently, 
Igboeli et al. (2012) found increases in EC50 values from L. salmonis collected in 2011 
compared with values obtained by Westcott et al. (2008) from 2002 to 2005 suggesting 
the development of emamectin benzoate resistance had occurred over time.  
In conclusion, this analysis presents evidence of a reduction in emamectin 
benzoate treatment effectiveness over time and between geographical locations in New 
Brunswick, Canada, for the period of time examined (2004 to 2008). These results 
correspond with the clinical picture witnessed in the field of a decline in treatment effect 
which became a concern in 2008 (Chang et al. 2011). Further investigation is warranted 
to confirm the underlying cause of this decline in treatment effectiveness. In addition, 
more collaboration is needed between laboratory investigations of sea lice sensitivity to 
treatment agents and epidemiological analyses of treatment events and sea lice trends 
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which would allow for a more holistic understanding of the development of parasiticide 
resistance in the aquatic environment. 
  
86 
 
2.6 Acknowledgements 
The authors would like to thank Drs. Leighanne Hawkins and Stacy Fielding of 
Cooke Aquaculture Inc. along with Drs. Mark Moore and Dan MacPhee of Maritime 
Veterinary Services Ltd. for kindly providing the data for this study. The authors would 
also like to thank Atlantic Innovation Fund and the provincial government partners 
(New Brunswick Department of Agriculture, Aquaculture, and Fisheries; Nova Scotia 
Department of Fisheries and Aquaculture; Prince Edward Island Department of 
Fisheries, Aquaculture and Rural Development; and Newfoundland and Labrador 
Department of Fisheries and Aquaculture) along with the Prince Edward Island 
Department of Innovation and Advanced Learning for providing the funding for this 
project.  
87 
 
2.7 Literature cited   
Armstrong R, MacPhee D, Katz T, Endris R (2000) A field efficacy evaluation of 
emamectin benzoate for the control of sea lice on Atlantic salmon. Can Vet J 
41:607-612  
Boxaspen K (2006) A review of the biology and genetics of sea lice. ICES J Mar Sci 
63:1304-1316  
Bravo S, Sevatdal S, Horsberg TE (2008) Sensitivity assessment of Caligus 
rogercresseyi to emamectin benzoate in Chile. Aquaculture 282:7-12  
Campbell PJ, Hammell KL, Dohoo IR, Ritchie G (2006) Randomized clinical trial to 
investigate the effectiveness of teflubenzuron for treating sea lice on Atlantic 
salmon. Dis Aquat Org 70:101-108  
Chang BD, Page FH, Beattie MJ, Hill BW (2011) Sea louse abundance on farmed 
salmon in the southwestern New Brunswick area of the Bay of Fundy. In: Jones 
S, Beamish R (eds) Salmon lice: an integrated approach to understanding 
parasite abundance and distribution. Wiley-Blackwell, Oxford, UK, p 83-115  
Costello MJ (2009) The global economic cost of sea lice to the salmonid farming 
industry. J Fish Dis 32:115-118  
Denholm I, Devine GJ, Horsberg TE, Sevatdal S, Fallang A, Nolan DV, Powell R 
(2002) Analysis and management of resistance to chemotherapeutants in salmon 
lice, Lepeophtheirus salmonis (Copepoda: Caligidae). Pest Manag Sci 58:528-
536  
Gustafson L, Ellis S, Robinson T, Marenghi F, Endris R (2006) Efficacy of emamectin 
benzoate against sea lice infestations of Atlantic salmon, Salmo salar L.: 
evaluation in the absence of an untreated contemporary control. J Fish Dis 
29:621-627  
Heuch PA, Gettinby G, Revie CW (2011) Counting sea lice on Atlantic salmon farms - 
empirical and theoretical observations. Aquaculture 320:149-153 
Hogans WE (1995) Infection dynamics of sea lice, Lepeophtheirus salmonis, parasitic 
on Atlantic salmon (Salmo salar) culture in marine waters of the lower Bay of 
Fundy. Can Tech Rep Fish Aquat Sci:1-9  
Hogans WE, Trudeau DJ (1989) Preliminary studies on the biology of sea lice, Caligus 
elongatus, Caligus curtus and Lepeophtheirus salmonis (Copepoda: Caligoida) 
parasitic on cage-cultured salmonids in the lower Bay of Fundy. Can Tech Rep 
Fish Aquat Sci: 1-14  
88 
 
Horsberg TE (2012) Avermectin use in aquaculture. Curr Pharm Biotechnol 13:1095-
1102  
Igboeli OO, Fast MD, Heumann J, Burka JF (2012) Role of P-glycoprotein in 
emamectin benzoate (SLICE®) resistance in sea lice, Lepeophtheirus salmonis. 
Aquaculture 344-349:40-47  
Johnson SC, Albright LJ (1991a) The developmental stages of Lepeophtheirus salmonis 
(Kroyer, 1837) (Copepoda: Caligidae). Can J Zool 69:929-950  
Johnson SC, Albright LJ (1991b) Development, growth, and survival of Lepeophtheirus 
salmonis (Copepoda: Caligidae) under laboratory conditions. J Mar Biol Assoc 
UK 71:425-436  
Lees F, Baillie M, Gettinby G, Revie CW (2008a) The efficacy of emamectin benzoate 
against infestations of Lepeophtheirus salmonis on farmed Atlantic salmon 
(Salmo salar L) in Scotland, 2002-2006. PLoS One 3:e1549  
Lees F, Baillie M, Gettinby G, Revie CW (2008b) Factors associated with changing 
efficacy of emamectin benzoate against infestations of Lepeophtheirus salmonis 
on Scottish salmon farms. J Fish Dis 31:947-951 
Lees F, Gettinby G, Revie CW (2008c) Changes in epidemiological patterns of sea lice 
infestation on farmed Atlantic salmon, Salmo salar L., in Scotland between 1996 
and 2006. J Fish Dis 31:259-268 
Murray AG, Peeler EJ (2005) A framework for understanding the potential for emerging 
diseases in aquaculture. Prev Vet Med 67:223-235  
O'Halloran J, Hogans WE (1996) First use in North America of azamethiphos to treat 
Atlantic salmon for sea lice infestation: procedures and efficacy. Can Vet J 
37:610-611  
Revie CW, Gettinby G, Treasurer JW, Wallace C (2005) Evaluating the effect of 
clustering when monitoring the abundance of sea lice populations on farmed 
Atlantic salmon. J Fish Biol 66:773-783 
Revie CW, Hollinger E, Gettinby G, Lees F, Heuch PA (2007) Clustering of parasites 
within cages on Scottish and Norwegian salmon farms: alternative sampling 
strategies illustrated using simulation. Prev Vet Med 81:135-147  
Robertsen B (2011) Can we get the upper hand on viral diseases in aquaculture of 
Atlantic salmon? Aquacult Res 42:125-131  
89 
 
Saksida SM, Morrison D, Revie CW (2010) The efficacy of emamectin benzoate against 
infestations of sea lice, Lepeophtheirus salmonis, on farmed Atlantic salmon, 
Salmo salar L., in British Columbia. J Fish Dis 33:913-917 
Saksida S, Constantine J, Karreman GA, Donald A (2007) Evaluation of sea lice 
abundance levels on farmed Atlantic salmon ( Salmo salar L.) located in the 
Broughton Archipelago of British Columbia from 2003 to 2005. Aquacult Res 
38:219-231 
Schram TA (1993) Supplementary descriptions of the developmental stages of 
Lepeophtheirus salmonis (Kroyer, 1837) (Copepoda: Caligidae). In: Boxshall 
GA, Defaye DD (eds) Pathogens of wild and farmed fish: sea lice. Ellis 
Horwood, New York, p 30-50  
Sevatdal S, Horsberg TE (2003) Determination of reduced sensitivity in sea lice 
(Lepeophtheirus salmonis Krøyer) against the pyrethroid deltamethrin using 
bioassays and probit modelling. Aquaculture 218:21-31 
Sevatdal S, Copley L, Wallace C, Jackson D, Horsberg TE (2005) Monitoring of the 
sensitivity of sea lice (Lepeophtheirus salmonis) to pyrethroids in Norway, 
Ireland and Scotland using bioassays and probit modelling. Aquaculture 244:19-
27 
Stone J, Sutherland IH, Sommerville C, Richards RH, Endris RG (2000a) The duration 
of efficacy following oral treatment with emamectin benzoate against 
infestations of sea lice, Lepeophtheirus salmonis (Krøyer), in Atlantic salmon 
Salmo salar L. J Fish Dis 23:185-192 
Stone J, Sutherland IH, Sommerville C, Richards RH, Varma KJ (2000b) Commercial 
trials using emamectin benzoate to control sea lice Lepeophtheirus salmonis 
infestations in Atlantic salmon Salmo salar. Dis Aquat Organ 41:141-149  
Stone J, Sutherland IH, Sommerville C, Richards RH, Varma KJ (2000c) Field trials to 
evaluate the efficacy of emamectin benzoate in the control of sea lice, 
Lepeophtheirus salmonis (Krøyer) and Caligus elongatus Nordmann, 
infestations in Atlantic salmon Salmo salar L. Aquaculture 186:205-219 
Westcott JD, Stryhn H, Burka JF, Hammell KL (2008) Optimization and field use of a 
bioassay to monitor sea lice Lepeophtheirus salmonis sensitivity to emamectin 
benzoate. Dis Aquat Org 79:119-131  
White HC (1940) "Sea lice" (Lepeophtheirus) and death of salmon.  J Fish Res Board 
Can 5:172-175  
  
90 
 
Chapter 3 Detection of emamectin benzoate tolerance emergence in different 
life stages of sea lice (Lepeophtheirus salmonis) on farmed Atlantic salmon (Salmo 
salar L.) 2 
3.1 Abstract 
Emamectin benzoate has been used to treat sea lice (Lepeophtheirus salmonis) 
infestations on farmed Atlantic salmon (Salmo salar). Recent evidence suggests a 
reduction in effectiveness in some locations. A major challenge in the detection of 
tolerance emergence can be the typically low proportion of resistant individuals in a 
population during the early phases. The objectives of this study were to develop a 
method for determining differences in temporal development of tolerance between sea 
lice life stages, and to explore how these differences might be used to improve 
monitoring of treatment effectiveness in a clinical setting.  
This study examined two data sets based on records of sea lice abundance 
following emamectin benzoate treatments from the west coast of Scotland (2002 to 
2006) and from New Brunswick, Canada (2004 to 2008). Life stages were categorized 
into two groups (adult females and the remaining mobile stages) to examine trends in 
mean abundance and treatment effectiveness. Differences between the two groups in 
emamectin benzoate effectiveness were found by year and location suggesting that an 
important part of monitoring drug resistance development in aquatic ecto-parasites may 
be the need to focus on key life stages.  
 
                                                 
2
 P.G. Jones, K.L. Hammell, G. Gettinby, C.W. Revie.  Detection of emamectin benzoate tolerance 
emergence in different life stages of sea lice (Lepeophtheirus salmonis) on farmed Atlantic salmon (Salmo 
salar L.).  Journal of Fish Diseases. 
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3.2 Introduction 
The development of treatment resistance in sea lice has become problematic for 
salmon farming regions around the world. Increased tolerance has been noted in sea lice 
for dichlorvos and azamethiphos (organophosphates) in Scotland and Norway (Jones et 
al. 1992, Roth et al. 1996, Fallang et al. 2004). Resistance in sea lice to azamethiphos 
has been documented at a molecular level in adult female sea lice, Lepeophtheirus 
salmonis (Krøyer 1837), from Canada and Norway (Fallang et al. 2004). There have 
been anecdotal reports of pyrethroid treatment failures in Scotland (Sevatdal et al. 
2005). Reduced sensitivity to deltamethrin through the use of bioassays has been 
documented in a population of sea lice in Norway with a history of treatment failures 
(Sevatdal & Horsberg 2003). Reductions in emamectin benzoate treatment effectiveness 
have been demonstrated through the use of field data collected in Scotland (Lees et al. 
2008a, Lees et al. 2008b) and the Bay of Fundy region of Atlantic Canada (Jones et al. 
in press), but not in British Columbia, Canada (Saksida et al. 2010). A reduction in the 
sensitivity of sea lice to emamectin benzoate based on laboratory bioassays has been 
documented in Chile, although the predominant species of sea lice in that region is 
Caligus rogercresseyi (Boxshall & Bravo 2000) (Bravo et al. 2008). 
Emamectin benzoate is an avermectin product which has been used to treat sea 
lice in many salmon farming regions around the world. This product is mixed with feed 
and administered to farmed salmon over the course of seven consecutive days. When 
effective, emamectin benzoate generally provides an extended period of protection 
against all stages of sea lice found on Atlantic salmon (Salmo salar L.) (Stone et al. 
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2000). Emamectin benzoate has been used in New Brunswick since 1999 and in 
Scotland since 2000. 
Resistance development against products used in the treatment of parasites 
associated with terrestrial animals has been documented and can be a consequence of 
repeated use in populations (Wolstenholme et al. 2004). The mechanism of resistance 
development can occur through a number of alterations in the organism. Overall, 
resistance usually develops through the prevention of a drug reaching the molecular 
WDUJHWRUWKURXJKLQDFWLYDWLRQRIWKHGUXJRUWKHGUXJ¶VDFWLRQV(Denholm et al. 2002, 
Wolstenholme et al. 2004). The rate at which resistance develops can depend on a 
multitude of factors, such as the resistance mechanism, impacts on the host from 
infestation, frequency of chemical/pesticide use, and biology of the parasite (Denholm et 
al. 2002).  
Genes conferring resistance to a particular parasiticide likely already exist in the 
population and resistance emergence is inevitable since use of the treatment selects for 
these resistance factors. A major obstacle with early detection of resistance is during the 
preliminary stages when the genes conferring resistance occur at such low frequency in 
a population that detection can be challenging, if not impossible. Typically, by the time 
drug resistance becomes evident in a population through documentation of multiple 
treatment failures, the resistant alleles are already prevalent in the population.  
Various methods have been used for the detection and confirmation of ecto-
parasiticide resistance. Bioassays are a valuable tool for detection of reduced sensitivity 
in sea lice populations especially when the underlying resistance mechanism is unknown 
(Denholm et al. 2002), but they can be expensive to perform and usually require long 
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term monitoring of populations in order to detect differences. Due to the tendency for 
bioassays to use large numbers of viable sea lice, consume personnel time, and require 
experienced laboratory staff to set up and interpret the results, they have been used 
mostly for research and not extensively as a tool for resistance monitoring and detection 
(Westcott et al. 2008). Further research is being conducted to develop modified 
bioassays which may be more practical for field use. Reports of treatment failures have 
been another method of potential resistance detection, but these reports need to be 
interpreted with caution as there can be many reasons for treatment failures. More 
recently, the use of epidemiological methods using field collected data has been shown 
to be an effective method for monitoring of changes in treatment effectiveness 
(Gustafson et al. 2006, Lees et al. 2008a, Lees et al. 2008b). 
Being aware of differences in resistance development patterns or trends between 
life stages or sexes may contribute valuable insight for early detection. In sea lice, 
differences in sensitivity patterns have been noted in previous studies where adult 
female lice were found to be less sensitive than other life stages to some bath treatment 
products (Roth et al. 1996, Treasurer et al. 2000). The reasons for this variability were 
not determined but may have to do with differences between adult female sea lice and 
the other mobile stages. Potentially, anatomical differences, such as a larger size or 
thicker cuticle, might result in adult female sea lice being more tolerant to bath 
treatments. In addition, there have been anecdotal reports from producers and 
veterinarians that adult female sea lice sometimes remained on salmon following 
treatment with emamectin benzoate, leading to suspicions of emerging tolerance (L. 
Hawkins, personal communication, 2012). Churcher & Basáñez (2009) suggested that 
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host selection is important when sampling. This may be relevant for many parasitic 
diseases where abundance and predilection of certain parasite life stages on the host may 
be evident. Sea lice abundance on the host fish can vary by age or size of fish, as well as 
time of year and sometimes site location (Saksida et al. 2007, Lees et al. 2008c).  
The objectives of this study were to determine if there was evidence of a 
temporal pattern to treatment responses that varied across sea lice life stages, and then to 
explore how these differences might be used to better monitor treatment effectiveness in 
a clinical or field setting. A simple and robust method for monitoring of treatment 
effectiveness using field collected data would be beneficial as a tool to be used in 
conjunction with bioassays and other molecular level tests for resistance detection. In 
this analysis, we separated total mobile sea lice (L. salmonis) into two groups: adult 
females, which contained both non-gravid and gravid adult females, and other mobiles, 
consisting of pre-adult males and females as well as adult males. In this article, the use 
of the term sea lice can be taken to be synonymous with L. salmonis. 
3.3 Materials and methods 
In this particular study, we only examined emamectin benzoate treatment 
response of L. salmonis as this is the more pathogenic and more prevalent species on 
farmed Atlantic salmon in the North Atlantic Ocean. Two data sets were examined in 
this study: one from New Brunswick, Canada, encompassing the years 2004 to 2008 and 
the other from the west coast of Scotland covering the years 2002 to 2006, neither of 
which had previously been used to examine treatment effectiveness at the sea lice life 
stage level. The New Brunswick data was retrieved from a number of fish farming 
companies through their own veterinarians or private veterinarians contracted by the 
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company, whereas the Scottish data was retrieved from one company who owned and 
managed all sites.  
Inclusion criteria used in this investigation were similar to methods used in Lees 
et al. (2008a, 2008b) in Scotland. For each data set, historical sea lice count data and 
treatment records were examined and treatment episodes were selected based on specific 
study inclusion criteria (Lees et al. 2008a, Lees et al. 2008b). In order to be included, 
each treatment episode had a pre-treatment count within 16 days prior to the start of 
treatment, and a minimum of three post-treatment sea lice evaluations during the 12 
weeks following initiation of treatment. A specific sea lice count was only included 
when at least two cages were sampled with a minimum of five fish per cage examined. 
All data available on each sampling date were used in this analysis to allow for as large 
a sample size as possible. Any treatment that had a notation in the record regarding only 
partial site treatment or split site treatment was excluded from this analysis. A treatment 
episode was followed for 12 weeks after treatment initiation or until another treatment 
was applied. 
A problem emerged when examining the historical data records in that sea lice 
count data were not uniformly collected and recorded across years in New Brunswick. 
For example, in the New Brunswick data, one sub-set was categorized into the following 
groups: chalimus stages, mobiles, and gravid females while another segment was 
organized into chalimus, pre-adults, adult males, non-gravid adult females, and gravid 
adult females. Given the different classification systems present, we chose to group the 
data in a way which would reduce the chance of error. Since sea lice counters likely 
varied in their ability to correctly classify the life stages, we felt that counters were 
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probably able to accurately distinguish between adult female sea lice and the rest of the 
mobile lice stages. Adult female sea lice are larger (approximately 10.0 mm in length) 
and often have egg strings attached, while the other mobile lice stages (adult male, pre-
adult female, and pre-adult male) are of a similar size (2.9-5.4 mm in length) (Johnson 
& Albright 1991); therefore, we chose to group pre-adult males, pre-adult females, and 
DGXOWPDOHVWRJHWKHU7KLVJURXSZLOOEHUHIHUUHGWRDVµRWKHUPRELOHV¶7KHRWKHUJURXS
consisted of adult female lice, both gravid and non-gravid.  
The analysis consisted of an evaluation of treatment trends which were 
categorized and examined by year, using two methods. First, mean abundance (mobile 
sea lice per fish per farm) for each treatment episode was calculated prior to treatment 
initiation and for each of the twelve weeks following the start of treatment for which 
data were available. These values were then averaged by year. Second, treatment 
effectiveness as a percentage of the pre-treatment abundance was evaluated. Treatment 
effectiveness was determined by the following equation: Treatment effectiveness = 
(post-treatment mean abundance / pre-treatment mean abundance) * 100%. Both the 
abundance and effectiveness were calculated separately for the two groups of life stages 
and summarized at the farm level.  
In order to further explore differences in treatment effectiveness between the two 
groups, a theoretical model was examined based on the assumption that rates of 
resistance development were likely to vary by life stage. This involved tracking changes 
in values of treatment effectiveness within the two groups by year together with total 
mobile sea lice. Post-treatment weeks 2 through 9 were combined as this appeared to be 
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the range when treatment effect was most evident (duration of treatment effect). 
Treatment effectiveness was then summarized by year using the calculation listed above.  
A multilevel mixed effects linear regression model was developed to formally 
evaluate statistical significance of treatment effect between adult female lice and the 
other mobile lice over time. The outcome variable for this model was percent 
effectiveness (percentage of pre-treatment abundance remaining in the post-treatment 
period). Given than this dependent variable was found to be right skewed, the data were 
logarithmically transformed [ln (x + 1)] resulting in a more normally distributed 
outcome variable. Predictor variables were screened for unconditional associations with 
the outcome variable and those with p-values <0.15 were kept for inclusion in the model 
during the model building process. Model building was carried out manually with 
interactions among key variables evaluated as part of the process. Residuals at both the 
week and treatment episode levels were checked for normality and homoscedasticity. 
Predictor variables evaluated during the model building process were year, life stage 
group (adult female or other mobile), location (New Brunswick or Scotland), pre-
treatment mobile mean abundance, and pre-treatment chalimus mean abundance.  
Software used to analyze the data was Microsoft Excel 2007 (Microsoft Canada 
Co., 1950 Meadowvale Blvd., Mississauga, Ontario, Canada) and Stata/IC 12 
(StataCorp LP, 4905 Lakeway Drive, College Station, Texas, USA). Microsoft Excel 
2007 was used to manage and format the data, and to create the mean abundance and 
efficacy graphs. Stata 12 was used to perform the trend and treatment effectiveness 
analysis along with the statistical models.  
 
98 
 
3.4 Results  
After excluding treatment episodes based on the inclusion criteria, 114 treatment 
episodes remained in the New Brunswick data while 108 treatment episodes qualified in 
the Scottish data. In each data set, all major farming areas in each region were 
represented. There were 54 farms represented out of approximately 80-90 farms in New 
Brunswick. Data from Scotland were drawn from 66 farms owned by one company and 
treatment episodes meeting the inclusion criteria were associated with 47 farms. In each 
region, the number of active fish farming sites varied by year.  
3.4.1 Trends in New Brunswick post-treatment sea lice abundance and treatment 
effectiveness 
From 2004 to 2006 (Figure 3.1), satisfactory clearance of adult female lice was 
generally achieved during the post-treatment period with levels of less than 1 adult 
female per fish being observed beginning two weeks after the start of treatment. Week 1 
was classified as days zero through six during which time treatment was still being 
administered. In 2007, adult female lice dropped to less than 1 adult female per fish for 
weeks 4 through 9 but began fluctuating around 1 louse for the remaining weeks. 
Generally treatment effect was starting to wane by week 9 or 10 and the data tended to 
be sparser in the later weeks of a treatment episode. In 2008, there was an increase in 
post-treatment abundance of adult female lice in all weeks compared to pre-treatment 
quantities. Overall abundance of other mobile lice tended to be higher compared with 
adult female lice (Figure 3.2). This finding was not surprising as the other mobile group 
consists of pre-adult male, adult male, and pre-adult female lice combined. Essentially 
in the early years, good clearance was achieved with abundance levels decreasing to less 
than 1 other mobile lice per fish at some point during the post-treatment period from 
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2004 to 2007. A change in this trend was noted in 2008 where the lowest level achieved 
was 2.4 other mobile lice per fish, although there was still a decrease from the pre-
treatment abundance, in contrast to adult female lice in which no decrease was observed.  
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Figure 3.1  Mean abundance of adult female Lepeophtheirus salmonis pre-treatment and 
1-12 weeks after commencement of treatment on Atlantic salmon farms in New 
Brunswick, Canada, from 2004 to 2008.  
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Figure 3.2  Mean abundance of mobile (except adult females) Lepeophtheirus salmonis, 
pre-treatment and 1-12 weeks after commencement of treatment on Atlantic salmon 
farms in New Brunswick, Canada, from 2004 to 2008.  
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3.4.2 Trends in Scotland post-treatment sea lice abundance and treatment 
effectiveness 
Data from Scotland (Figures 3.3 & 3.4) were summarized in the same format as 
for New Brunswick data. In general, pre-treatment abundance levels were higher on 
Scottish salmon farms. Adequate removal of adult female lice (i.e. less than 2 adult 
females per fish) was found to occur in all years except 2006. In 2006, adult females 
decreased to less than 1 adult female per fish, but this finding did not happen until nine 
weeks after treatment initiation. In earlier years (2002 to 2004), maximum treatment 
effect was found by week 4 or 5. Other mobile lice were found to decrease to less than 1 
other mobile per fish in all years assessed. Again, time to maximum effectiveness was 
delayed in the last year to approximately week 9.  
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Figure 3.3  Mean abundance of adult female Lepeophtheirus salmonis, pre-treatment 
and 1-12 weeks after commencement of treatment on Atlantic salmon farms in Scotland 
from 2002 to 2006. 
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Figure 3.4  Mean abundance of mobile (except adult female) Lepeophtheirus salmonis, 
pre-treatment and 1-12 weeks after commencement of treatment on Atlantic salmon 
farms in Scotland from 2002 to 2006. 
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3.4.3 Theoretical model for evaluation of differences in tolerance emergence 
A theoretic graph (Figure 3.5) was developed based on the premise that the 
pattern of resistance development would follow an exponential growth curve. We also 
speculated that tolerance development to emamectin benzoate in adult female lice would 
advance at a more rapid rate compared to other mobile stages. In New Brunswick, by 
2008, there was a dramatic difference between the degree of treatment effect in adult 
female lice compared to other mobiles (Figure 3.6). Tolerance was sufficiently advanced 
that, compared to pre-treatment levels, there was an increase in the number of adult 
female lice present in the post-treatment period. Since effectiveness calculations were 
based on percent of pre-treatment abundance, anything over 100% constituted an 
increase in abundance from pre-treatment values.  
An interesting finding from Figure 3.6 was that the traditional method of 
monitoring effectiveness, using total mobiles, basically tracked the effectiveness of the 
other mobile lice group. This was likely due to the larger number of other mobiles 
compared to adult females as a group, in other words, the majority of total mobiles 
consisted of other mobiles. In 2008, a marked difference arose between adult female and 
other mobile lice groups. By not tracking the effectiveness of emamectin benzoate on 
adult females, emergence of resistance in this stage may have been overlooked.  
Summarized Scottish data is presented in Figure 3.7. Although differences 
between stages were not as dramatic in the Scottish data, an increase in values for adult 
female lice (i.e. decreased treatment effect) compared to the other stages was apparent. 
Figures 3.6 and 3.7 display effectiveness values against year (high values = poor 
treatment response). These curves appear to be more exponential in shape rather than 
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linear. Although they are not true rate of resistance development curves, they do indicate 
a decreased treatment response over time.
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Figure 3.5  Theoretic graph comparing the values for emamectin benzoate treatment 
effectiveness (as a percentage of pre-treatment abundance) in groups of Lepeophtheirus 
salmonis life stages. 
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Figure 3.6  Effectiveness of emamectin benzoate (% of pre-treatment abundance) by 
year against Lepeophtheirus salmonis (total mobiles, adult females, and other mobiles 
except adult females) with post-treatment weeks 2-9 combined on farmed Atlantic 
salmon in the Bay of Fundy, New Brunswick, Canada.  
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Figure 3.7  Effectiveness of emamectin benzoate (% of pre-treatment abundance) by 
year against Lepeophtheirus salmonis (total mobiles, adult females, and other mobiles 
except adult females) with post-treatment weeks 2-9 combined on farmed Atlantic 
salmon in Scotland.  
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3.4.4 Statistical model for evaluation of differences in treatment effect 
For this model, treatment effectiveness values from both countries were 
combined into one data set to facilitate comparison of effectiveness values between 
locations as well as amongst years, and additionally, to improve statistical power of the 
analysis. The Scottish data had two treatment episodes removed as they were found to 
be outliers. The Scottish data set covered the years 2002 to 2006 while the data from 
New Brunswick included 2004 to 2008; previous analysis had shown the changes in 
treatment effectiveness were most evident in the final year of each set of data (Lees et 
al. 2008a, Lees et al. 2008b, Jones et al. in press). Therefore, for the purpose of coupled 
analysis, data VHWVZHUHDVVLJQHGD³\HDU´YDOXHRIone through five, representing a two 
year offset between locations in terms of actual calendar years. 
The multilevel mixed effects linear regression was used for the examination of 
statistical differences between values of treatment effectiveness in the two groups (adult 
female and other mobile lice) (Table 3.1). A two level model was constructed with 
treatment episode as a random effect (i.e. effectiveness measurements within treatment 
episode). Significant variables remaining in the final model were location (Scotland or 
New Brunswick, Canada), year, and life stage group. Pre-treatment mean abundance of 
mobile lice was included as a variable (forced covariate) because of the strong 
association with post-treatment lice counts and the potential confounding effect due to 
associations with other variables in the model. There were significant interactions 
between year and life stage group as well as year and location.  
A significant interaction between year and life stage group indicated that the 
value of treatment effectiveness in the two groups depended upon the year (Figure 3.8). 
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Higher values, indicating a reduced treatment effect, were found for adult females 
compared to other mobiles. Differences in effectiveness between adult female and other 
mobile lice appeared to be less dramatic in the Scottish data although the difference 
occurred more consistently over several years. In addition, treatment effect varied by 
location and year with values in Scotland being lower than those in New Brunswick 
(Figure 3.9). The trends in decreasing emamectin benzoate effectiveness (increase in 
values) appeared to follow a similar trajectory over the five years studied, though the 
speed of decline in effectiveness seemed to be more rapid in New Brunswick.  
Model diagnostics included calculating residuals at both life stage group and 
treatment levels. Normal probability plots found residuals to be fairly normally 
distributed at both the individual group level as well as at the treatment level. Plots to 
evaluate homoscedasticity (residuals against predicted values) found no evidence of 
extreme differences in levels of variation.  
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Table 3.1  Results of the linear mixed model - evaluation of emamectin benzoate 
treatment effectiveness for the treatment of Lepeophtheirus salmonis on farmed Atlantic 
salmon in New Brunswick, Canada (2004-2008) and Scotland (2002-2006). (Baseline 
values are adult females in year 5 in New Brunswick, Canada, and pre-treatment level 
(ln (x+0.1) where the lowest x value was 0)) 
 
Variable Category 
Coefficient 
(log 
transformed) 
SE p-
value 
95% Confidence 
Interval 
 
    Lower Upper 
 
    
  
Stage Other mobiles -0.499 0.162 0.002 -0.817 -0.181 
Year 1 -2.812 0.678 0.000 -4.140 -1.483 
 
2 -2.345 0.421 0.000 -3.170 -1.521 
 
3 -1.419 0.405 0.000 -2.212 -0.626 
 
4 -1.115 0.368 0.002 -1.837 -0.394 
Stage * Year Other mob*yr1 0.372 0.322 0.248 -0.259 1.002 
 
Other mob*yr2 0.496 0.231 0.032 0.043 0.949 
 
Other mob*yr3 0.544 0.224 0.015 0.106 0.983 
 
Other mob*yr4 0.366 0.214 0.086 -0.052 0.785 
Location Scotland -0.749 0.427 0.080 -1.587 0.089 
Location*Year Scotland*yr1 0.407 0.855 0.634 -1.269 2.082 
 
Scotland*yr2 0.271 0.621 0.662 -0.945 1.488 
 
Scotland*yr3 -0.180 0.595 0.762 -1.347 0.986 
 
Scotland*yr4 0.192 0.557 0.730 -0.900 1.284 
Pre-treatment  
abundance 
(log transformed) 
 
0.008 0.079 0.923 -0.148 0.163 
Constant  
 
4.865 0.286 0.000 4.304 5.426 
Random Effects 
Parameters 
 Estimate SE  95% Conf Interval 
 
Treatment: 
Identity 
 
Variance 
(constant) 
1.574 0.183 
 
1.253 1.977 
 
Variance 
(residual) 0.510 0.053  0.415 0.626 
LR test vs. linear regression: chibar2(01) =    152.95  Prob >= chibar2 = 0.0000 
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Figure 3.8  Interaction plot of life stage by year. Graph shows effectiveness (as a 
percentage of pre-treatment abundance) of emamectin benzoate in adult female and 
µRWKHUPRELOH¶Lepeophtheirus salmonis on farmed Atlantic salmon by year category for 
combined data from Scotland and New Brunswick, Canada. 
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Figure 3.9  Interaction plot of location by year. Effectiveness (as a percentage of pre-
treatment abundance) of emamectin benzoate in mobile Lepeophtheirus salmonis on 
farmed Atlantic salmon in New Brunswick, Canada, and Scotland by year category. 
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3.5 Discussion 
Results of this analysis indicated a reduction in treatment effectiveness over 
time; however it does not confirm the presence of emamectin benzoate resistant sea lice 
populations. Confirmation of resistance development is normally through the 
identification of biochemical or biophysical properties known to convey an advantage to 
parasites which can be transferred genetically to offspring. Recent research has shown 
that increased expression of P-glycoprotein mRNA was found in field collected sea lice 
from 2011 compared to 2002 (Igboeli et al. 2012). The same study concluded that 
emamectin benzoate may be a substrate for P-glycoprotein and upregulation of this 
transporter protein may be linked with tolerance development. While there can be other 
contributing factors for isolated reductions in treatment effectiveness or treatment 
failures, we can speculate that at least some of the reductions in treatment effect over 
time were due to emamectin benzoate resistance development in populations of sea lice.  
As mentioned previously, a major road block in the early detection of resistance 
development is the low frequency at which resistance initially starts in a population. 
Hastings (2001) discussed resistance development occurring in a logarithmic growth 
pattern. This type of pattern occurs in such a way that once resistance frequency is 
sufficiently high enough to detect, resistance is already rapidly spreading through the 
population. We expanded on this idea by postulating that resistance development might 
occur at different rates or to variable extents between sea lice life stages. If these life 
stages are monitored appropriately, then resistance development, or at least strong 
indications of emergence, could potentially be detected at an earlier stage. The current 
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study found that resistance appeared to be more advanced in adult female sea lice 
compared to a group containing the rest of the mobile stages.  
Overall treatment effectiveness for each location was examined by plotting 
effectiveness values against time in years for each location. Scottish data exhibited 
lower, but steadier, increases over time while New Brunswick data displayed a more 
rapid increase. Although slope differences cannot be explained by a descriptive analysis 
such as this, we speculate that different use of sea lice treatment products may have 
contributed to differences in tolerance development. Review of available treatment 
records for New Brunswick showed that emamectin benzoate accounted for greater than 
95% of all treatments during the study period. In Scotland, during the time period 
investigated, approximately half of the available treatment episodes reviewed indicated 
the use of emamectin benzoate (Lees et al. 2008b). We surmise that the use of several 
products in Scotland may have slowed the rate of parasiticide resistance development. If 
true, this supports the recommendation of alternating between two unrelated products in 
an effort to help delay resistance development (Denholm et al. 2002).  
While our results showed that there was a more advanced decrease in treatment 
response of adult females (i.e. increase in effectiveness values) in 2008 in the New 
Brunswick data, while this was somewhat less evident in 2006 in the Scottish data. This 
study design could not confirm why there was such a fluctuation in effectiveness values. 
These data from Scotland were a mix of three different regions and differences may 
have occurred due to regional (within country) disparities in resistance development. 
Previous studies examining the same data set (Lees et al. 2008a, Lees et al. 2008b) 
found that emamectin benzoate treatment effectiveness on total mobiles varied by 
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region. It is possible that regions where treatment effect was still adequate could be 
obscuring data from areas where resistance was developing.  
Tracking of individual life stages (rather than groups) may provide more detailed 
information since some of the individual stage information is obscured when the life 
stages are grouped. However, effective use of such monitoring methods requires that sea 
lice life stages are correctly categorized and recorded during sea lice counts. The 
granularity of New Brunswick data did not allow precise evaluation but the Scottish data 
contained classification of individual stages. One weakness of this study is the potential 
for inaccurate classification of sea lice life stages in these historical data. Companies 
collected and recorded data for their own in-house use hence there was no need to 
ensure that their data collection methods were consistent with other companies. Some 
variation in the accuracy of sea lice counts between companies was expected, but it was 
believed that any impact would have been minimized by the large sample sizes of both 
data sets. Many individuals performed regular sea lice monitoring and, while staff had 
received training, the experience level of the counter could vary. In the future, more 
attention to stage classification during collection of field data and routine sea lice counts 
would be needed for the individual stage method to be used. 
This study did not consider the type of resistance mechanisms that occur in sea 
lice to emamectin benzoate. The genetic processes associated with resistance 
development may influence the rate at which resistance genes accumulate within a 
population (Jackson & Coop 2000). If a parasiticide can affect multiple parasite stages, 
then the parasite could potentially develop drug resistance in several different ways 
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should the resistance gene that protects one life stage from the actions of the drug fail to 
protect another (Churcher & Basáñez 2009). 
Jackson & Coop (2000) have conveyed that there is a lack of simple robust 
techniques for field detection of emerging drug resistance. This study examined field 
collected sea lice treatment data for differences in treatment effectiveness between 
groups of life stages. In the past, development of resistance in different sexes or life 
stages could only be detected through the use of bioassays. A benefit to this type of 
trend analysis is that these types of data are already collected for monitoring of 
treatment effectiveness, therefore would not result in extra cost to the company or work 
for farm staff. However, practical use of these methods does not eliminate the need for 
other forms of treatment response monitoring, in particular the use of laboratory studies, 
such as bioassays.  
When emamectin benzoate worked effectively in New Brunswick, Canada, 
bioassay results showed that pre-adult female lice were more sensitive to the drug than 
pre-adult male lice (Westcott et al. 2008). This seems contradictory to the findings in 
this study but there are several points to consider: the bioassay study examined sea lice 
from the Bay of Fundy from 2002 to 2005 and the bioassays only examined pre-adult 
male and pre-adult female lice. In a previous study on the effectiveness of emamectin 
benzoate in the Bay of Fundy from 2004 to 2008, results showed that treatments were 
effective for 2004 and 2005, which overlapped with the bioassay study (Jones et al. in 
press). This current study looks at life stages grouped by adult females and the 
remaining mobile stages (pre-adult males and females and adult males). There may be a 
change occurring in female sea lice during the moult from a pre-adult to an adult 
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resulting in differences in sensitivity patterns. Sex and life stage differences have been 
found in intestinal parasites of terrestrial animals (Le Jambre et al. 1995, Le Jambre et 
al. 2000). Sevatdal et al. (2005) reported that adult female lice were less sensitive to a 
pyrethroid product compared to pre-adult and adult male lice through the use of a 
bioassay. The same study also suggested that results of bioassays using pre-adult stages 
cannot necessarily be extrapolated to outcomes expected under field conditions where 
the removal of adult female lice is essential.  
There can be several reasons for differences in results between bioassays and 
field collected data analysis. First, bioassays are performed in a laboratory where sea 
lice are immersed in a sea water bath containing a diluted pesticide. Sea lice absorb the 
pesticide through the cuticle and perhaps some of the product is ingested orally. In 
contrast, sea lice on farmed salmon are exposed to the product through ingestion of 
mucus and possibly skin of fish which have consumed the pesticide in medicated feed. 
Second, bioassays require separation of individual life stages and the stages of choice 
are evaluated, whereas the current study categorized life stages into two groups. If there 
were differences in the sensitivity of adult male lice compared to adult female lice, they 
may not have been detected since effects isolated to adult males may have been 
diminished by the presence of pre-adult stage lice. Third, sample location and time are 
both important factors to consider with the interpretation of either test. Resistance 
emergence appears to be a dynamic process and distinct changes can occur from year to 
year; therefore, comparing field results to bioassay results from different years may lead 
to contradictory findings. Treatment effectiveness can vary by location (Lees et al. 
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2008a, Lees et al. 2008b, Jones et al. in press) and, as a result, outcomes of both 
methods could vary depending on location. 
In this study, the emergence of emamectin benzoate resistance development in 
sea lice appeared to be more advanced in adult female lice than in the other mobile lice 
combined. Taking this into consideration, perhaps a different approach should be taken 
when planning bioassays for monitoring drug sensitivity. In the past, pre-adults have 
been used exclusively by some laboratories for performing sea lice bioassays (Sevatdal 
& Horsberg 2003, Sevatdal et al. 2005). However, there should be some consideration 
given to targeting of life stages when selecting samples for bioassays or other laboratory 
tests for resistance (Westcott et al. 2008). Variability in both bioassays and treatment 
response analysis reflects the fact that resistance emergence is a dynamic process and 
prediction of changes in sea lice sensitivity is challenging. No single method is likely to 
suffice for monitoring sea lice sensitivity. Combining evidence from multiple sources 
for industry and policy decision makers will optimize treatment effectiveness over the 
longest term. 
In conclusion, this analysis found differences in emamectin benzoate 
effectiveness between the two groups of life stages by year and location. Changes in sea 
lice sensitivity to emamectin benzoate were not necessarily synchronized in all life 
stages. A difference in the rates of resistance development between locations was noted, 
with resistance developing more rapidly in New Brunswick compared to Scotland. 
These results suggest that an important part of monitoring for drug resistance in aquatic 
ecto-parasites includes a focus on key life stages.  
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Chapter 4 General Discussion 
4.1 Main findings of thesis 
The objective of Chapter 1 was to examine relevant literature and to determine 
the most appropriate epidemiological methods for evaluating the field use of emamectin 
benzoate in the treatment of sea lice (Lepeophtheirus salmonis). A broad range of 
scientific literature on the epidemiology and management of sea lice along with 
resistance development to parasiticides was reviewed. While resistance development to 
emamectin benzoate in sea lice is not novel, there have been few published reports and, 
in regard to salmon farming in Atlantic Canada, there is little documented evidence of 
treatment resistance; indeed the entire topic of sea lice epidemiology on the east coast of 
Canada over the past decade has been largely absent from the scientific literature. This 
is in contrast to the situation on the west coast of Canada or that seen for a number of 
European countries such as Ireland, Scotland, and Norway.  
Chapter 2 examined and described the effectiveness of emamectin benzoate in 
the treatment of L. salmonis on farmed Atlantic salmon (Salmo salar) in New 
Brunswick. Trends in treatment effectiveness, as well as post-treatment sea lice 
abundance levels were examined. Factors associated with post-treatment sea lice 
abundance and treatment outcome (success or failure) were evaluated using appropriate 
statistical models. Temporal and spatial developments of tolerance to emamectin 
benzoate in populations of sea lice in the Bay of Fundy were found. This was in 
agreement with the clinical perspective in the field at the time when there were 
anecdotal reports of treatment failures. Since that time, emamectin benzoate has been 
found to be ineffective in many field situations and other treatment agents are now 
commonly used. 
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Chapter 3 further expanded the evaluation of changes in treatment effectiveness 
by examining two data sets for rates of change in separate sea lice life stages. One data 
set was from New Brunswick, Canada, while the other was from the west coast of 
Scotland. Due to differences in data collection methods, sea lice had to be grouped into 
two broad categories: adult female L. salmonis (gravid and non-gravid) and all the other 
mobile stages of L. salmonis. The preferred method would have been to examine each of 
the life stages separately but one of the limitations in using field data is that 
classifications may not be achievable after the event. It is difficult to identify some 
individual life stages in the field, particularly the differentiation between pre-adult 
female, adult male, and pre-adult male stages. In the end, differences in tolerance 
development between the two groups were found. This difference was more evident in 
New Brunswick than in Scotland. Resistance was found to have developed at different 
rates between the two data sets, with the New Brunswick data showing a faster rate of 
resistance development compared to Scotland. This was an interesting finding and, 
while the cause of this difference was not confirmed, the use of emamectin benzoate 
differed in these regions. In Scotland, a variety of treatment products were in use in 
addition to emamectin benzoate. In New Brunswick, emamectin benzoate was used in 
over 95% of the treatments applied during the study period. Denholm et al. (2002) listed 
the use of a single product as a key risk factor for the development of resistance.  
This project used historical field-collected salmon production and health 
management data. There are benefits and drawbacks in the use of these types of 
historical data. Several concerns regarding historical data were mentioned in Chapter 2 
and this topic was also discussed in Lees et al. (2008b). These concerns include issues 
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such as differences in experience level and training of sea lice counters, and the 
exclusion of treatment episodes not meeting certain inclusion criteria. Overall, many of 
these concerns were overcome or minimized by the use of a large data set. The data set 
analyzed for Chapter 2 was similar in size with Lees et al. (2008a, 2008b) and was 
substantially larger than those of Gustafson et al. (2006) and Saksida et al. (2010). Also 
with this project, there were concerns around the classification of sea lice life stages. 
This is important when examining individual life stages or groups of life stages for 
changes in treatment effectiveness. An ideal scenario would be to reliably monitor pre-
adult male, pre-adult female, adult male, and adult female lice as individual stages.  
We used epidemiological methods for monitoring changes in treatment 
effectiveness around the use of emamectin benzoate. This approach had been initially 
used in the evaluation of treatment effectiveness and then expanded to monitor for 
changes in treatment effect both spatially and temporally. This type of approach allows 
for the examination of large amounts of historical data.  
Production data is often incomplete or unbalanced and these factors require 
consideration during the model selection process. For these reasons, hierarchical linear 
regression models were used in Chapters 2 and 3. A unique feature of the study in 
Chapter 2 was the use of a multilevel mixed model for the evaluation of the effects of 
multiple variables on post-treatment sea lice abundance. There has only been a series of 
two papers (Lees et al. 2008a; Lees et al. 2008b) which made use of statistical modelling 
to examine factors associated with treatment effectiveness. Chapter 2 expanded on 
previous work by using a multilevel model which accounted for the hierarchical 
structure of the data and the time ordering of the follow-up measurements. This type of 
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analysis allowed for the follow-up observations to be grouped into individual treatment 
episodes. This approach accounted for the fact that post-treatment observations within a 
treatment episode are not independent. A correlation structure (structure of the 
covariance matrix) was used to account for variability in the sea lice counts between 
weeks (repeated measures) within each treatment episode. A correlation structure is an 
extension of the linear mixed model. By use of the Toeplitz correlation structure, it was 
shown that subsequent counts were correlated within each episode but only up to a 
certain point (6 weeks apart) after which the correlation decreased significantly. This 
type of structure is not commonly found in published epidemiological literature and 
particularly not in aquatic epidemiology. Revie et al. (2002) examined the correlation 
between counts and found that the strongest correlations occurred at three weeks and six 
weeks apart. The counts three weeks apart were negatively correlated which would 
correspond to a treatment response of a reduction in sea lice abundance. The counts six 
weeks apart were positively correlated which could be explained by an increase in sea 
lice abundance following treatment. The majority of treatments included in that study 
were bath treatments which have an immediate and short-acting impact on sea lice 
populations. 
4.2 Alternative approaches to analysis 
Developing methods for the evaluation of treatment effectiveness without the use 
of a control group can be challenging. Some criticisms could be made over the use of 
pre-treatment sea lice levels as the baseline upon which to gauge the degree of change in 
sea lice abundance following treatment. The issue relates to the amount of variability 
which occurs with pre-treatment sea lice abundance. Problems were encountered with 
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treatment episodes which had very low pre-treatment abundance and thus presented 
difficulties in determining treatment effect. We used a window of 16 days to determine 
pre-treatment levels. Thus, if a count was done at 14 days, the sea lice levels could be 
significantly different by the time the treatment started. One alternative might be to 
calculate the mean of all the counts within the 16 day window which might give a more 
accurate assessment of sea lice abundance. The current study based effectiveness as a 
percentage of the pre-treatment abundance. A treatment was considered effective if it 
achieved a reduction to less than 40% of the pre-treatment lice level. An alternative 
method for determining treatment effectiveness might be to base treatment success on 
lice being reduced below a predetermined value (e.g. significantly less than a ³trigger 
level´ if such a regulation is in place for a particular region). Another alternative might 
be the development of a scoring system which would determine treatment effectiveness 
using a number of factors rather than a single calculation. An example might be to use 
the method employed in Chapter 2 along with an additional component of a score for the 
minimum level of abundance achieved (i.e. above or below a predetermined threshold).  
In this study, treatment effectiveness was evaluated at the site level, meaning that 
all cages were averaged together to determine a site level mean for pre-treatment 
abundance as well as in each of the post-treatment weeks. Cage level analysis was not 
chosen since the same cages were often not evaluated at each follow-up point (i.e. would 
not be able to consistently match pre- and post-treatment counts for each cage). It would 
be interesting to carry out the same evaluation at cage level and determine if the results 
are comparable to the site level evaluations. Jiminez et al. (2012) evaluated the 
effectiveness of bath treatments in Norway at both a cage and site level. That study 
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calculated treatment effectiveness with the use of point estimates and confidence 
intervals at both the cage and site level. They found the quasi-Poisson method with a 
90% confidence interval to be the most robust measurement of bath treatment 
effectiveness. Evaluation at the site level can result in overdispersion (i.e. variance being 
greater than the mean) given that lice abundance can vary between cages. The use of 
cage level treatment effect monitoring can minimize overdispersion. The proportion of 
acceptable treatments was larger at the site level compared to cage level when evaluated 
at the same confidence level (Jiminez et al. 2012). Jiminzez et al. demonstrated that 
there is benefit to the examination of site and cage level treatment effectiveness. They 
also showed that the use of confidence intervals rather than a point estimate may give 
more information to those responsible for the evaluation of treatment response. Chapter 
2 examined emamectin benzoate effectiveness at a site level. Further investigation into 
cage level effectiveness would be a reasonable next step and could provide some 
interesting insights regarding heterogeneity of effectiveness across a site.  
Chapter 3 evaluated two groups of sea lice life stages for changes in treatment 
effectiveness over time and geographical location. An alternative method to the one 
presented in Chapter 3 was also explored and this is presented in Appendix A. In 
generalWKHDEXQGDQFHRIµRWKHUPRELOH¶OLFH tends to be higher in comparison to adult 
female lice making it difficult to evaluate for changes in absolute abundance between 
the two groups. In an effort to determine if resistance developed in adult female lice 
prior to other stages or if there were differences in the abundance of adult female lice 
over time, the proportion of the total mobile lice population which were adult females 
was calculated. The theory behind this calculation was that if resistance truly developed 
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in one stage before another then there should be an increase in the presence of that 
particular life stage as resistance emerged over time. We observed that there appeared to 
be an increase in the proportion of adult female lice over time which corresponded to 
decreases in effectiveness of emamectin benzoate. This finding may be relevant to 
future monitoring of resistance emergence in populations of sea lice and warrants further 
exploration. Further examination of the two data sets used in Chapter 3 by this method 
may provide further insight into early indicators for resistance emergence. 
4.3 Future directions 
A general epidemiological analysis of sea lice trends in the Bay of Fundy region 
would be an important next step. There has been limited formal epidemiological 
analysis of sea lice trends. While some factors can be extrapolated from other locations, 
there are likely local variables which can cause variations in sea lice abundance. 
Knowing the risk factors for increased sea lice abundance or any disease process in the 
aquatic environment is important when planning a preventative medicine program. In 
the Bay of Fundy, we found variations in treatment effectiveness by location. We have 
reason to believe that there are natural differences in sea lice trends based on pre-
treatment levels and studies from other salmon farming regions. Examination of these 
trends through the use of historical sea lice count data would allow for tracking of these 
changes. This may be important in the future planning of salmon farm locations in that 
region. If some locations were found to be at high risk for severe sea lice infestations, 
relocation of those sites may be warranted. New Brunswick uses Aquaculture Bay 
Management Areas (ABMAs) for the grouping of farming sites. Currently, each ABMA 
practices single year class stocking, mandatory fallow periods (i.e. four months per site, 
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two months per ABMA), and a three year rotation system (Chang et al. 2011). Some 
ABMAs have a higher density of farms than others. This variable would be interesting 
to evaluate as off-farm infection pressure would likely vary depending on overall farm 
density within an ABMA. Findings from such a study may aid in the restructuring and 
relocation of farms to better control sea lice populations. 
There needs to be more collaboration between laboratory studies and the analysis 
of field data to aid in the early detection of resistance emergence. Unfortunately, there is 
no single screening test which will reliably allow for the detection of resistance 
emergence in the early stages. Currently, the best plan for monitoring of resistance 
would involve a collaborative effort between the evaluation of field efficacy and 
laboratory monitoring of sea lice sensitivity. While monitoring through the use of field 
data should include as many treatment episodes as possible, laboratory bioassays might 
benefit from targeted sampling since these tests are costly and require considerable time 
and effort. Perhaps suspect treatment failures should be followed up with a review of 
field data, treatment information and environmental conditions and then these sites 
could be targeted for future monitoring through bioassays. In British Columbia, 
researchers have begun to monitor treatment effectiveness in the field in conjunction 
with instituting the examination of sea lice sensitivity to emamectin benzoate through 
the use of laboratory bioassays (Saksida et al. 2012). 
There has been little epidemiologic research in the area of sea lice on farmed 
Atlantic salmon in the Bay of Fundy. The research presented in this thesis adds insights 
around the treatment of sea lice and the development of resistance. With further research 
(i.e. epidemiologic analysis of sea lice population trends), knowledge can be expanded 
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to provide a more solid foundation for decision making in regards to salmon farming 
and disease management in this area. With respect to treatment monitoring, this study 
demonstrated the importance of monitoring individual life stages together with total 
mobiles. Through a careful examination of sea lice epidemiology and treatment 
effectiveness, we believe that this research furthers the knowledge of the subject area on 
the east coast of Canada. With further understanding, the development of improved 
monitoring and management practices may delay the emergence of resistance in the 
future and allow for earlier detection of emergence. This work provides solid evidence 
of the development of emamectin benzoate resistance prior to the problem becoming 
evident to producers and the rest of the industry in 2009 and suggests the basis for 
monitoring of parasiticide resistance development in the future. 
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Chapter 5 Appendix 
Appendix A An alternative method for tracking resistance development to 
emamectin benzoate in separate sea lice (Lepeophtheirus salmonis) life stages 
Chapter 3 evaluated two groups of life stages for changes in treatment 
effectiveness over time and location. An alternative method to the one presented in 
Chapter 3 was explored. In generalWKHDEXQGDQFHRIµRWKHUPRELOH¶OLFe tended to be 
higher in comparison to adult female lice making comparisons between the two groups 
challenging. In an effort to determine if resistance developed in adult females prior to 
the other stages or if there were differences in the ratio of adult females to other mobiles 
which occurred over time, an approach which calculated the proportion of total mobiles 
which were adult females was considered. In theory, if resistance developed in one stage 
before another then there should be an increase in the proportion of that life stage as 
resistance emerged over time.  The year 2004 was eliminated from the analysis as that 
year only had seven treatment episodes and all the episodes involved data collected from 
one company. Given that there were concerns around misclassification error, ensuring 
that data was from a variety of sources minimized these concerns. Weeks were grouped 
into pairs in the post-treatment period to ensure the results were robust.  
An increase in the percentage of adult females over time was observed. The pre-
treatment proportion of adult female lice in 2005 was 12.8% (Table A.1). In 2006, a 
larger proportion of total mobiles were adult females at pre-treatment at 22.3% and 2007 
had a similar value at 23.8%. In 2008, the pre-treatment percentage adult female lice 
was 15.2%. During the post-treatment period, in 2006, the percentage of adult females 
varied from 12.1% to 17.1%. A marked increase was noted in 2007, although the lowest 
proportion of adult females was 19.2% but this may not have been an accurate indicator 
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(during the last time period where data tends to be sparser and treatment effect was 
starting to wane). The next lowest proportion was 25.4%, which may have been a more 
accurate indicator of the true value. It should be noted that in 2007 there was not much 
change in the percentage of adult females present from the pre-treatment evaluation to 
the post-treatment assessments. In essence, the proportion of adult females present on 
fish during the post-treatment period did not decrease much from the pre-treatment 
value of 23.8%. In 2008, a similar finding was noted with an increased proportion of 
adult females being found. 
A ratio of the mean proportion of adult female L. salmonis during the post-
treatment period to the proportion pre-treatment abundance of adult female lice by year 
was calculated. This ratio increased with each successive year (Table A.1). This 
indicator shows that there was an increase in the presence of adult females which 
coincided with a reduction in the effectiveness of emamectin benzoate. In fact, in 2007 
the ratio was 1.1 which was one year before a significant reduction in treatment 
effectiveness was noted (Chapter 2). The use of such an indicator warrants further 
investigation through the examination of similar data sets to determine if such a pattern 
is routinely present in the development of resistance in sea lice to treatment products. 
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Table A.1   Proportion of total mobile Lepeophtheirus salmonis that are adult females 
(AF) (+/- standard error) for emamectin benzoate treatment episodes by year in New 
Brunswick, Canada. a  
Sample Week 2005 2006 2007 2008 
Pre-Tx 12.8 (3.1) 22.3 (4.4) 23.8 (4.3) 15.2 (2.7) 
3 & 4 8.9 (3.1) 16.6 (6.7) 26.7 (3.7) 23.3 (3.6) 
5 & 6 1.6 (1.1) 13.4 (6.0) 29.3 (4.4) 30.6 (5.0) 
7 & 8 8.8 (7.0) 14.2 (4.3) 25.4 (5.0) 27.2 (4.9) 
9 & 10 5.5 (3.4) 17.1 (5.1) 25.5 (5.2) 16.1 (3.5) 
11 & 12 3.9 (2.2) 12.1 (5.5) 19.2 (5.1) 14.3 (5.6) 
Mean proportion of AF 
during post-treatment period  5.7 14.7 25.2 22.3 
Ratio of mean proportion of 
AF post-treatment to 
proportion of AF pre-
treatment b 
0.4 0.7 1.1 1.5 
 
a Proportion total mobile L. salmonis that are adult females = (mean abundance adult 
females/mean abundance total mobiles)*100% 
b Ratio of mean proportion of adult females post-treatment to proportion of adult females pre-
treatment  = (mean proportion of adult females during post-treatment period/ proportion of adult 
females at pre-treatment) 
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One of the possible downfalls to using the proportion of adult female lice to 
track resistance emergence is that changes in the ratios of life stages may be occurring 
naturally in the environment. In other words, there may be some variation in the levels 
of one life stage over another. This has been noted during the winter months when adult 
females tend to be the life stage that persist on fish during these colder months. There 
are likely regional variations to this finding as well, with some areas having overall 
higher abundance than others. Another possibility could be variation between counters 
of sea lice, although the easiest stage to differentiate is probably adult females given that 
they are significantly larger than the other mobile stages. Lastly, there is variation in the 
pre-treatment levels of the percentage of total mobiles which are adult females. There 
were increases found in 2006 and 2007 and then a decrease for 2008. It could not be 
determined if this was influenced by the emergence of emamectin benzoate resistance or 
due to natural variations in sea lice populations. One could speculate that if resistance 
were evolving, then the life stages more prone to resistance development would be 
present in higher proportions. The cause of this variation cannot be determined in this 
study but it is interesting that an increase in the proportion of adult females does appear 
to coincide with a decrease in the effectiveness of emamectin benzoate over time.  
 
 
 
 
